## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2022-01-26_Virtual Town Hall 77_fixnames.md
last updated: 2025-01-05 Created QA Sections
link pdf: https://www.fda.gov/media/156146/download?attachment
link youtube: https://youtu.be/hp5ceXLlpd0
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on COVID-19 Test Development Guidance

QA Block 1-1
CLARIFIED QUESTION: What should EUA holders review in their letter of authorization with regard to distributors and changes to labeling?
CLARIFIED ANSWER: EUA holders should review their letter of authorization's conditions to see when they need to notify FDA and obtain concurrence. Typically, they must inform the FDA about new distributors and receive concurrence for updated labeling but do not need concurrence for adding distributors without labeling changes.
VERBATIM QUESTION: What should EUA holders review in their letter of authorization with regard to distributors and changes to labeling?
VERBATIM ANSWER: Generally, we recommend that all EUA holders refer to their conditions of authorization in their letter of authorization to determine what needs to be sent to FDA and in which cases they need concurrence from FDA prior to implementation. In general, the conditions of authorization typically state that an EUA holder must tell the FDA of any new distributors and must have concurrence from FDA prior to implementation of any updated labeling, including any new brand names. So, the concurrence is generally only if there is updated labeling. If you are adding a new distributor without changing any labeling, we will generally acknowledge receipt, but you do not need to wait for concurrence. And that is, again, dependent on what is in your letter of authorization, but that is the typical situation for most EUAs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA letter of authorization, Distributor notification, Labeling changes
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What is the process for developers to get feedback on submitting a 510k for molecular SARS-CoV-2 tests?
CLARIFIED ANSWER: FDA recommends developers submit a presubmission to discuss their approach. Developers can send an email to the EUA mailbox for feedback. Those who have already submitted a presubmission do not need to take additional actions and will receive feedback through that process.
VERBATIM QUESTION: What is the process for developers to get feedback on submitting a 510k for molecular SARS-CoV-2 tests?
VERBATIM ANSWER: We've generally recommended that developers submit a presubmission to discuss their approach, and we've stated that previously on this call many times. At this point, we are able to provide feedback more rapidly. So we welcome any developers that are considering a 510k for a molecular SARS-CoV-2 test to send an email to the EUA mailbox requesting feedback regarding submission of a 510k. And for those developers that have already submitted a presubmission, you don't need to do anything differently. We will get that feedback to you through your presubmission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k submission, Molecular SARS-CoV-2 tests, Feedback process
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: Do developers who have already made presubmissions for 510k need to take additional action to receive feedback?
CLARIFIED ANSWER: Developers who have already submitted a presubmission for a 510k do not need to take additional action as they will receive feedback through their presubmission.
VERBATIM QUESTION: Do developers who have already made presubmissions for 510k need to take additional action to receive feedback?
VERBATIM ANSWER: For those developers that have already submitted a presubmission, you don't need to do anything differently. We will get that feedback to you through your presubmission.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k presubmissions, Developer feedback process
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: Why was the IVD EUA Molecular and Antigen webpage updated to include whether assays are single or multiple target tests?
CLARIFIED ANSWER: The IVD EUA Molecular and Antigen webpage was updated to help users identify which tests might be more affected by viral mutations.
VERBATIM QUESTION: Why was the IVD EUA Molecular and Antigen webpage updated to include whether assays are single or multiple target tests?
VERBATIM ANSWER: And then on Friday of last week, we also updated the IVD EUA Molecular and Antigen web pages to add information about whether each authorized assay is a single or multiple target test. And this is intended to better inform potential users which tests are more susceptible to changes in performance due to viral mutations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: IVD updates, Test susceptibility to mutations, Single and multiple target tests
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What steps should a developer take if their COVID-19 tests are shipped or stored in freezing temperatures?
CLARIFIED ANSWER: FDA added an FAQ and issued social media guidance on addressing tests shipped or stored in freezing temperatures.
VERBATIM QUESTION: What steps should a developer take if their COVID-19 tests are shipped or stored in freezing temperatures?
VERBATIM ANSWER: On Saturday the 22nd, we added an FAQ and put out some social media regarding the use of tests that are shipped and left outside in freezing temperatures.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Freezing temperatures impact on tests, FDA guidance, Test shipping/storage conditions
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: How can developers submit comments for clarification on the draft guidance titled 'The Transition Plan for Medical Devices Issued EUAs During the COVID-19 Public Health Emergency'?
CLARIFIED ANSWER: FDA advises developers to submit comments to the docket if there are unclear points in the draft guidance, identifying areas that need additional clarity.
VERBATIM QUESTION: How can developers submit comments for clarification on the draft guidance titled 'The Transition Plan for Medical Devices Issued EUAs During the COVID-19 Public Health Emergency'?
VERBATIM ANSWER: Since that guidance has been issued in draft for comment and not for implementation, if there are points about the guidance that are unclear, we recommend that you submit a comment to the docket indicating areas that could benefit from added clarity.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: draft guidance comments, EUA transition plan, clarification process
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What details should be included in an email to the EUA Templates mailbox to receive feedback on managing current test development plans or transitions under the draft guidance?
CLARIFIED ANSWER: FDA recommends including sufficient details about your current plans for transitioning emergency use tests or submission of a 510k when emailing the EUA Templates mailbox, to ensure appropriate feedback is provided.
VERBATIM QUESTION: What details should be included in an email to the EUA Templates mailbox to receive feedback on managing current test development plans or transitions under the draft guidance?
VERBATIM ANSWER: If you have a question about how to manage your current plans for moving forward now with your emergency use test or with a 510k, we recommend that you send an email to the EUA Templates mailbox with sufficient details so that we can provide appropriate feedback for your particular situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test development plans, Draft guidance transition, EUA Templates mailbox
REVIEW FLAG: False


#### 2. Telehealth Proctor Requirements for Home Rapid Tests

QA Block 2-1
CLARIFIED QUESTION: What is required for a telehealth provider for home rapid tests?
CLARIFIED ANSWER: Tests using telehealth proctoring must be validated with the proctor as part of the test. Developers should submit an EUA request showing accurate test performance with proctoring to ensure proper telehealth use and readings.
VERBATIM QUESTION: What is required for a telehealth provider for home rapid tests?
VERBATIM ANSWER: Sure, yeah, so tests that use a telehealth proctor are validated with the proctor as part of the test and are authorized as such based on that performance data. So a developer that's looking to include telehealth proctor as part of their test should submit an EUA request demonstrating appropriate performance of the test with proctoring. This allows the FDA to ensure that the tests are able to be accurately performed via telehealth and accurately read via telehealth.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: telehealth proctor requirements, home rapid tests, EUA submission
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What performance data is needed to validate a test with telehealth proctoring?
CLARIFIED ANSWER: Tests involving telehealth proctors must be validated with the proctor included as part of the test. Developers should submit an EUA request showing the test's performance with proctoring to ensure accurate telehealth usage and reading.
VERBATIM QUESTION: What performance data is needed to validate a test with telehealth proctoring?
VERBATIM ANSWER: Tests that use a telehealth proctor are validated with the proctor as part of the test and are authorized as such based on that performance data. So a developer that's looking to include telehealth proctor as part of their test should submit an EUA request demonstrating appropriate performance of the test with proctoring. This allows the FDA to ensure that the tests are able to be accurately performed via telehealth and accurately read via telehealth.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test validation, telehealth proctoring, EUA submission
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: How should a developer demonstrate the accuracy of at-home tests under telehealth supervision in their EUA submission?
CLARIFIED ANSWER: Developers should submit an EUA request demonstrating the test's performance with telehealth proctoring to ensure accurate test operation and results under telehealth supervision.
VERBATIM QUESTION: How should a developer demonstrate the accuracy of at-home tests under telehealth supervision in their EUA submission?
VERBATIM ANSWER: Tests that use a telehealth proctor are validated with the proctor as part of the test and are authorized as such based on that performance data. So a developer that's looking to include telehealth proctor as part of their test should submit an EUA request demonstrating appropriate performance of the test with proctoring. This allows the FDA to ensure that the tests are able to be accurately performed via telehealth and accurately read via telehealth.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: telehealth supervision, EUA submission, test accuracy
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Does the FDA specifically review the ability of telehealth proctors to guide users and interpret results?
CLARIFIED ANSWER: The FDA reviews performance data for tests with telehealth proctors to ensure accurate test performance and interpretation via telehealth, as part of the EUA process.
VERBATIM QUESTION: Does the FDA specifically review the ability of telehealth proctors to guide users and interpret results?
VERBATIM ANSWER: Tests that use a telehealth proctor are validated with the proctor as part of the test and are authorized as such based on that performance data. So a developer that's looking to include telehealth proctor as part of their test should submit an EUA request demonstrating appropriate performance of the test with proctoring. This allows the FDA to ensure that the tests are able to be accurately performed via telehealth and accurately read via telehealth.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: telehealth proctor validation, EUA process, COVID-19 diagnostics
REVIEW FLAG: False


#### 3. Addressing Omicron Variant in Antigen Test Development

QA Block 3-1
CLARIFIED QUESTION: How should test developers address the omicron variant in clinical studies for new antigen tests?
CLARIFIED ANSWER: Test developers should include clinical data from omicron-infected patients in EUA submissions to ensure performance with the variant, consider broader test performance across known variants, and plan to monitor emerging mutations. FDA review expectations should be discussed with agency reviewers.
VERBATIM QUESTION: How should test developers address the omicron variant in clinical studies for new antigen tests?
VERBATIM ANSWER: Now, any new EUA requests should include clinical data from patients infected with omicron to ensure that the test performs well with this variant. As discussed in the policy for evaluating the impact of viral mutations on COVID-19 tests, the FDA considers performance across all known variants as well asâ€” OK. All right, so I'll continue with that one. We do consider performance across all known variants as well as the developer's plan for ongoing monitoring of new and emerging variants. As we saw with omicron, several tests were impacted by the mutations in the omicron, so this is an important review consideration. And we would ask that you discuss with your FDA reviewer the expectations in that regard.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: omicron variant, antigen test performance, EUA submissions
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What clinical data should be included in new EUA requests to address the omicron variant?
CLARIFIED ANSWER: New EUA requests should include clinical data from patients infected with omicron. FDA evaluates test performance across all known variants and reviews the developer's plan for monitoring new variants.
VERBATIM QUESTION: What clinical data should be included in new EUA requests to address the omicron variant?
VERBATIM ANSWER: Now, any new EUA requests should include clinical data from patients infected with omicron to ensure that the test performs well with this variant. As discussed in the policy for evaluating the impact of viral mutations on COVID-19 tests, the FDA considers performance across all known variants as well as the developer's plan for ongoing monitoring of new and emerging variants. As we saw with omicron, several tests were impacted by the mutations in the omicron, so this is an important review consideration. And we would ask that you discuss with your FDA reviewer the expectations in that regard.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical data for omicron, EUA requests, viral mutations in tests
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: What is the FDA's policy for evaluating the impact of viral mutations on COVID-19 tests?
CLARIFIED ANSWER: The FDA reviews test performance across all known variants and expects developers to include plans for ongoing monitoring of new variants. Developers should consult with their FDA reviewers on specific expectations.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: As discussed in the policy for evaluating the impact of viral mutations on COVID-19 tests, the FDA considers performance across all known variants as well as the developer's plan for ongoing monitoring of new and emerging variants. As we saw with omicron, several tests were impacted by the mutations in the omicron, so this is an important review consideration. And we would ask that you discuss with your FDA reviewer the expectations in that regard.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Impact of viral mutations, Test performance monitoring, Omicron variant
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: How does the FDA evaluate a test developer's plan for ongoing monitoring of new and emerging variants?
CLARIFIED ANSWER: The FDA evaluates a test developer's plan for monitoring new and emerging variants by reviewing test performance against all known variants and considering impacts from mutations, such as those observed with omicron. Developers should discuss monitoring expectations with their FDA reviewer.
VERBATIM QUESTION: How does the FDA evaluate a test developer's plan for ongoing monitoring of new and emerging variants?
VERBATIM ANSWER: We do consider performance across all known variants as well as the developer's plan for ongoing monitoring of new and emerging variants. As we saw with omicron, several tests were impacted by the mutations in the omicron, so this is an important review consideration. And we would ask that you discuss with your FDA reviewer the expectations in that regard.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: monitoring emerging variants, test performance evaluation, developer-FDA communication
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What considerations should developers keep in mind regarding the impact of viral mutations, such as those in the omicron variant?
CLARIFIED ANSWER: FDA advises developers to include clinical data from patients infected with omicron to verify test performance and to ensure monitoring plans for variants. FDA also reviews the test's impact of viral mutations like omicron as part of EUA evaluations.
VERBATIM QUESTION: What considerations should developers keep in mind regarding the impact of viral mutations, such as those in the omicron variant?
VERBATIM ANSWER: Now, any new EUA requests should include clinical data from patients infected with omicron to ensure that the test performs well with this variant. As discussed in the policy for evaluating the impact of viral mutations on COVID-19 tests, the FDA considers performance across all known variants as well as the developer's plan for ongoing monitoring of new and emerging variants. As we saw with omicron, several tests were impacted by the mutations in the omicron, so this is an important review consideration. And we would ask that you discuss with your FDA reviewer the expectations in that regard.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Impact of viral mutations, Omicron variant, Test development
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What expectations should developers discuss with their FDA reviewer regarding test performance across known and emerging variants?
CLARIFIED ANSWER: FDA expects developers to consider test performance across all known variants, have a plan for monitoring emerging variants, and discuss these aspects with their FDA reviewer.
VERBATIM QUESTION: What expectations should developers discuss with their FDA reviewer regarding test performance across known and emerging variants?
VERBATIM ANSWER: We do consider performance across all known variants as well as the developer's plan for ongoing monitoring of new and emerging variants. As we saw with omicron, several tests were impacted by the mutations in the omicron, so this is an important review consideration. And we would ask that you discuss with your FDA reviewer the expectations in that regard.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test performance monitoring, variant impact, FDA reviewer expectations
REVIEW FLAG: False


#### 4. FDA Perspective on At-Home COVID Throat Swab Testing

QA Block 4-2
CLARIFIED QUESTION: What does the FDA require to demonstrate the safety of throat swabs for at-home COVID-19 diagnostics?
CLARIFIED ANSWER: The FDA is open to the use of throat swabs for at-home COVID-19 diagnostics if safety concerns are addressed. However, data shows lower sensitivities compared to nasal swabs and risks such as gagging and contamination. These challenges, along with variant-specific considerations, make throat swabs less favorable.
VERBATIM QUESTION: Will FDA consider throat swabs for at-home COVID-19 diagnostic tests?
VERBATIM ANSWER: The CDC does recommend that throat swabs be collected only by trained health care providers. While the FDA is open to the sample type for rapid tests with data demonstrating that the safety concerns have been addressed, there has been some new evidence published. That's a UCSF paper preprint that is on the slide deck and can be referred to. I will briefly outline the key findings from that paper. They examined the use of an oral cheek swab and what they call a throat swab, which I believe is an oropharyngeal swab, for use with one of the EUA-authorized rapid antigen tests. And they compared it to nasal swab and did have a PCR comparator as well. They found that either the cheek swab or the oropharyngeal swab alone had sensitivities that were considerably below the nasal swab alone. And when they obtained a combo nasal and oropharyngeal swab, the slight sensitivity improvement was, in their opinion, did not benefit testing enough considering the risks of oropharyngeal swabs, both to health care workers who might be performing it and to the user. There is frequently gagging and even throwing up. This can potentially spread disease within the health care environment, and obviously, would also be a problem at home in obtaining an adequate sample. Also, omicron may be unique in its tissue where it replicates more readily versus the other viral variants. For example, the previously mentioned South African paper showed for delta that a nasal swab was better than saliva in their hand. So it would be a lot of work to go through and validate something that may not be the best thing for patients or for care. And then you have the next variant come along and it returns it to being the nasal swab being the best. So I think that pretty much covers our thoughts on throat swabbing, so thank you.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Throat swabs for COVID-19 diagnostics, FDA safety requirements, Omicron variant testing
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: How does the sensitivity of oropharyngeal swabs compare to nasal swabs when used for rapid antigen tests?
CLARIFIED ANSWER: Oropharyngeal swabs show considerably lower sensitivity compared to nasal swabs when used for rapid antigen tests.
VERBATIM QUESTION: How does the sensitivity of oropharyngeal swabs compare to nasal swabs when used for rapid antigen tests?
VERBATIM ANSWER: They examined the use of an oral cheek swab and what they call a throat swab, which I believe is an oropharyngeal swab, for use with one of the EUA-authorized rapid antigen tests. And they compared it to nasal swab and did have a PCR comparator as well. They found that either the cheek swab or the oropharyngeal swab alone had sensitivities that were considerably below the nasal swab alone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Swab sensitivity comparison, Rapid antigen tests
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What are the safety risks associated with using oropharyngeal swabs for diagnostic purposes?
CLARIFIED ANSWER: Oropharyngeal swabs pose safety concerns such as gagging or vomiting, which can spread disease to health care workers and make at-home sampling challenging.
VERBATIM QUESTION: What are the safety risks associated with using oropharyngeal swabs for diagnostic purposes?
VERBATIM ANSWER: There has been some new evidence published. That's a UCSF paper preprint that is on the slide deck and can be referred to. I will briefly outline the key findings from that paper. They examined the use of an oral cheek swab and what they call a throat swab, which I believe is an oropharyngeal swab, for use with one of the EUA-authorized rapid antigen tests. And they compared it to nasal swab and did have a PCR comparator as well. They found that either the cheek swab or the oropharyngeal swab alone had sensitivities that were considerably below the nasal swab alone. And when they obtained a combo nasal and oropharyngeal swab, the slight sensitivity improvement was, in their opinion, did not benefit testing enough considering the risks of oropharyngeal swabs, both to health care workers who might be performing it and to the user. There is frequently gagging and even throwing up. This can potentially spread disease within the health care environment, and obviously, would also be a problem at home in obtaining an adequate sample.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Oropharyngeal swab safety, Diagnostic risks, COVID-19 testing
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Does the FDA consider the variability of virus behavior across different variants when assessing new sample types?
CLARIFIED ANSWER: The FDA considers the variability in virus behavior across variants, such as omicron and delta, when assessing sample types for diagnostic testing. For instance, the replication location of omicron differs from delta, impacting the effectiveness of sample types like nasal or saliva swabs.
VERBATIM QUESTION: Does the FDA consider the variability of virus behavior across different variants when assessing new sample types?
VERBATIM ANSWER: Also, omicron may be unique in its tissue where it replicates more readily versus the other viral variants. For example, the previously mentioned South African paper showed for delta that a nasal swab was better than saliva in their hand. So it would be a lot of work to go through and validate something that may not be the best thing for patients or for care. And then you have the next variant come along and it returns it to being the nasal swab being the best.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: variant behavior, sample type evaluation
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What are the additional validation requirements for introducing combined nasal and oropharyngeal swabs for testing?
CLARIFIED ANSWER: FDA noted that combined nasal and oropharyngeal swabs show marginal sensitivity improvement compared to nasal swabs, while posing risks like gagging, disease spread, and burdening providers and users at home.
VERBATIM QUESTION: What are the additional validation requirements for introducing combined nasal and oropharyngeal swabs for testing?
VERBATIM ANSWER: When they obtained a combo nasal and oropharyngeal swab, the slight sensitivity improvement was, in their opinion, did not benefit testing enough considering the risks of oropharyngeal swabs, both to health care workers who might be performing it and to the user. There is frequently gagging and even throwing up. This can potentially spread disease within the health care environment, and obviously, would also be a problem at home in obtaining an adequate sample.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation for combined swabs, Risks of oropharyngeal swabs
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: How might the risks of gagging or vomiting during oropharyngeal sample collection affect at-home diagnostic test approval?
CLARIFIED ANSWER: Gagging and vomiting, common with oropharyngeal swabs, increase the risk of disease spread in healthcare settings and pose challenges for home test sample collection.
VERBATIM QUESTION: How might the risks of gagging or vomiting during oropharyngeal sample collection affect at-home diagnostic test approval?
VERBATIM ANSWER: There is frequently gagging and even throwing up. This can potentially spread disease within the health care environment, and obviously, would also be a problem at home in obtaining an adequate sample.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: risks of oropharyngeal swabs, at-home diagnostics, safety concerns
REVIEW FLAG: False


#### 5. Responsibilities for Test Distribution and Laboratory Use Compliance

QA Block 5-1
CLARIFIED QUESTION: Does the test manufacturer have a duty to confirm a laboratory's CLIA registration status and type prior to shipment and maintain a record of this review, or does the responsibility fall with the laboratory to only use the test if qualified to do so?
CLARIFIED ANSWER: The EUA holder or authorized test distributor must confirm that they distribute tests only to appropriate laboratories and maintain adequate records of this process through inventory control.
VERBATIM QUESTION: Regarding FDA's condition of emergency use authorization limiting the emergency use of tests to authorized laboratories, does the manufacturer have a duty to confirm a laboratory's CLIA registration status and type prior to shipment and maintain a record of this review, or does the responsibility fall with the laboratory to only use if qualified to do so?
VERBATIM ANSWER: So it is the responsibility of the EUA holder or the authorized test distributor through the process of inventory control to adequately maintain records of authorized laboratories to which they distribute the test and the number of tests they distribute. So the EUA holder should be confirming that they are distributing only to appropriate laboratories.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA holder responsibilities, CLIA registration status, Distribution of tests
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Is it acceptable to use the candidate test to screen negative clinical matrix used for analytical validation instead of using an authorized or cleared asset?
CLARIFIED ANSWER: The FDA confirms that using the candidate test to confirm negative clinical matrix for analytical validation studies is acceptable.
VERBATIM QUESTION: Is it acceptable to use the candidate test to screen negative clinical matrix used for analytical validation instead of using an authorized or cleared asset?
VERBATIM ANSWER: Yes, it is acceptable to use the candidate test to confirm negative clinical matrix that will be used for analytical validation studies.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: candidate test for analytical validation, negative clinical matrix
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: What records of authorized laboratories and distributed test quantities should an EUA holder maintain as part of inventory control?
CLARIFIED ANSWER: The EUA holder must maintain records of authorized laboratories to which they distribute the test and the number of tests distributed. They must ensure tests are only sent to appropriate laboratories.
VERBATIM QUESTION: What records of authorized laboratories and distributed test quantities should an EUA holder maintain as part of inventory control?
VERBATIM ANSWER: So it is the responsibility of the EUA holder or the authorized test distributor through the process of inventory control to adequately maintain records of authorized laboratories to which they distribute the test and the number of tests they distribute. So the EUA holder should be confirming that they are distributing only to appropriate laboratories.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA holder responsibilities, Inventory control, Laboratory authorization
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Should EUA holders confirm they are distributing COVID-19 tests only to laboratories with appropriate qualifications?
CLARIFIED ANSWER: FDA clarifies that EUA holders or authorized test distributors must maintain records of tests distributed to authorized laboratories, ensuring they are distributed only to appropriately qualified laboratories.
VERBATIM QUESTION: Regarding FDA's condition of emergency use authorization limiting the emergency use of tests to authorized laboratories, does the manufacturer have a duty to confirm a laboratory's CLIA registration status and type prior to shipment and maintain a record of this review, or does the responsibility fall with the laboratory to only use if qualified to do so?
VERBATIM ANSWER: So it is the responsibility of the EUA holder or the authorized test distributor through the process of inventory control to adequately maintain records of authorized laboratories to which they distribute the test and the number of tests they distribute. So the EUA holder should be confirming that they are distributing only to appropriate laboratories.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA holder responsibilities, Laboratory qualification, Inventory control
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: What qualification procedures should labs follow when using RUO reagents from non-qualified lots for a modified version of the CDC assay?
CLARIFIED ANSWER: Labs using non-qualified lots of RUO reagents for a modified CDC assay should qualify each lot using CDC's procedures, which can be requested from FDA via the EUA mailbox. They should also follow the November 15 guidance to determine whether an EUA submission is needed.
VERBATIM QUESTION: What qualification procedures should labs follow when using RUO reagents from non-qualified lots for a modified version of the CDC assay?
VERBATIM ANSWER: So CDC, as we've discussed here before, has stopped qualifying lots for IDT to sell. They have stopped supporting their SARS-CoV-2-only assay. But they have also provided recommendations for laboratories that are using that CDC-- the original SARS-CoV-2 CDC assay to transition to another FDA authorized COVID-19 test. Laboratories that intend to continue performing testing using the RUO reagents, the non-qualified lots of reagents from IDT, should include qualification procedures for qualifying each lot of reagents that they purchase. CDC has provided their qualification procedures to FDA, and we're able to provide those to laboratories that need them. Excuse me. If you do need them, you can email the EUA mailbox and ask for those. Generally, since the CDC test is an authorized test, they still hold an EUA. Even though it is not being distributed any longer, labs may offer a modified version of the test under the modification policy that's included in the November 15 guidance. And so we do recommend that laboratories should consider the policies discussed in that November 15 version of the guidance the policy for coronavirus disease 2019 tests to determine whether they need to submit a new EUA request to the FDA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: RUO reagents, CDC assay modification, EUA policy
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: Do laboratories need to submit a new EUA request if they modify the original CDC SARS-CoV-2 assay according to the November 15 guidance?
CLARIFIED ANSWER: Laboratories modifying the original CDC SARS-CoV-2 assay under the November 15 guidance should review the policies in that guidance to determine if a new EUA request to the FDA is necessary.
VERBATIM QUESTION: Do laboratories need to submit a new EUA request if they modify the original CDC SARS-CoV-2 assay according to the November 15 guidance?
VERBATIM ANSWER: Generally, since the CDC test is an authorized test, they still hold an EUA. Even though it is not being distributed any longer, labs may offer a modified version of the test under the modification policy that's included in the November 15 guidance. And so we do recommend that laboratories should consider the policies discussed in that November 15 version of the guidance the policy for coronavirus disease 2019 tests to determine whether they need to submit a new EUA request to the FDA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA modification policy, CDC SARS-CoV-2 assay, November 15 guidance
REVIEW FLAG: False


#### 6. Criteria for Symptom Inclusion in Antigen Clinical Studies

QA Block 6-1
CLARIFIED QUESTION: For an over-the-counter antigen all-comers clinical study, is it acceptable to exclude individuals for symptom onset greater than a certain number of days to exclude individuals with lingering symptoms?
CLARIFIED ANSWER: FDA recommends recording symptom information but not excluding individuals based on symptoms for an all-comers study. Data from outside the intended-use date range should not be included in primary performance determinations.
VERBATIM QUESTION: For an over-the-counter antigen all-comers clinical study, is it acceptable to exclude individuals for symptom onset greater than a certain number of days to exclude individuals with lingering symptoms?
VERBATIM ANSWER: So if you're performing an all-comers study including symptomatic and asymptomatic individuals, you should not exclude anyone based on their symptoms. Instead, you should record this information, including for symptomatic individuals, the days since symptom onset. And you should also record any known exposures. Samples that are outside of the specified date range that you're requesting for your intended use should not be included in your primary determination of the agreement between your device and the comparator test. For example, if you're proposing an intended use for symptomatic individuals seven days post-symptom onset, then we would want to see performance data to support that intended use, and other data should be excluded from your primary determination of NPA and CPA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical study exclusion criteria, antigen test validation, data recording requirements
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: What information should be recorded for symptomatic individuals in an all-comers study?
CLARIFIED ANSWER: In an all-comers study, you should record the days since symptom onset for symptomatic individuals and any known exposures. Exclude data outside the intended use range from the primary performance evaluation.
VERBATIM QUESTION: What information should be recorded for symptomatic individuals in an all-comers study?
VERBATIM ANSWER: If you're performing an all-comers study including symptomatic and asymptomatic individuals, you should not exclude anyone based on their symptoms. Instead, you should record this information, including for symptomatic individuals, the days since symptom onset. And you should also record any known exposures. Samples that are outside of the specified date range that you're requesting for your intended use should not be included in your primary determination of the agreement between your device and the comparator test.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: data recording for symptomatic individuals, all-comers study guidelines, NPA and CPA exclusions
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Should known exposures be recorded during data collection in an all-comers study?
CLARIFIED ANSWER: Yes, known exposures should be recorded during an all-comers study, along with symptom onset information for symptomatic individuals.
VERBATIM QUESTION: Should known exposures be recorded during data collection in an all-comers study?
VERBATIM ANSWER: So if you're performing an all-comers study including symptomatic and asymptomatic individuals, you should not exclude anyone based on their symptoms. Instead, you should record this information, including for symptomatic individuals, the days since symptom onset. And you should also record any known exposures.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: all-comers study, data collection, known exposures
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: How should samples outside of the intended-use date range be treated in the primary determination of test agreement?
CLARIFIED ANSWER: Samples outside the intended-use date range must be excluded from the primary determination of test agreement. Performance data should support the specified intended use (e.g., symptomatic individuals seven days post-symptom onset).
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Samples that are outside of the specified date range that you're requesting for your intended use should not be included in your primary determination of the agreement between your device and the comparator test. For example, if you're proposing an intended use for symptomatic individuals seven days post-symptom onset, then we would want to see performance data to support that intended use, and other data should be excluded from your primary determination of NPA and CPA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test agreement, intended use, sample date range
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: What type of performance data is required to support an intended use for symptomatic individuals within a specific timeframe?
CLARIFIED ANSWER: Performance data specific to symptomatic individuals within the intended timeframe, such as seven days post-symptom onset, must be provided. Data outside this range should be excluded from primary analyses like NPA and CPA.
VERBATIM QUESTION: What type of performance data is required to support an intended use for symptomatic individuals within a specific timeframe?
VERBATIM ANSWER: If you're proposing an intended use for symptomatic individuals seven days post-symptom onset, then we would want to see performance data to support that intended use, and other data should be excluded from your primary determination of NPA and CPA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: performance data requirements, symptomatic individuals, testing timeframe
REVIEW FLAG: False


#### 7. FDA Performance Recommendations for Antigen Tests and Omicron Impact

QA Block 7-1
CLARIFIED QUESTION: Is FDA considering changing the recommendation for 80% PPA with a 70% lower bound of the 95% confidence interval for rapid antigen tests to address the challenge in detecting the omicron variant?
CLARIFIED ANSWER: FDA does not plan to change the performance recommendations for antigen tests, which already account for limitations in sensitivity compared to molecular tests. Updates will continue to be provided as new data on omicron or other variants emerges.
VERBATIM QUESTION: Is FDA considering changing the recommendation for 80% PPA with a 70% lower bound of the 95% confidence interval for rapid antigen tests to address the challenge in detecting the omicron variant?
VERBATIM ANSWER: FDA is not anticipating modifying the performance recommendations for antigen tests. Particularly as the use of rapid antigen tests increases, it's important that these tests are able to detect known variants, including omicron. Antigen tests are already labeled with a presumptive negative claim given the lower PPA than most molecular tests, and we do not anticipate reducing that performance recommendation any further. As additional information becomes available about the impact of omicron or future variants on diagnostic tests, we will continue to update the website with this information. And we do have a specific SARS-CoV-2 viral mutations impact on COVID-19 tests website that we update regularly.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Rapid antigen test recommendations, Omicron variant detection, Performance guidelines
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: What is FDA's rationale for maintaining the current performance recommendations for antigen tests?
CLARIFIED ANSWER: The FDA maintains the current performance recommendations for antigen tests to ensure they can detect known variants, including omicron. They consider the presumptive negative claim sufficient, given antigen tests have a lower PPA than molecular tests, and do not plan to reduce these performance standards. They will update their website as more information becomes available.
VERBATIM QUESTION: What is FDA's rationale for maintaining the current performance recommendations for antigen tests?
VERBATIM ANSWER: FDA is not anticipating modifying the performance recommendations for antigen tests. Particularly as the use of rapid antigen tests increases, it's important that these tests are able to detect known variants, including omicron. Antigen tests are already labeled with a presumptive negative claim given the lower PPA than most molecular tests, and we do not anticipate reducing that performance recommendation any further. As additional information becomes available about the impact of omicron or future variants on diagnostic tests, we will continue to update the website with this information. And we do have a specific SARS-CoV-2 viral mutations impact on COVID-19 tests website that we update regularly.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antigen test performance, Omicron variant impact, FDA recommendations
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: How does the FDA recommend developers address the potential reduced sensitivity of rapid antigen tests to new variants such as omicron?
CLARIFIED ANSWER: The FDA does not plan to modify antigen test performance recommendations despite reduced sensitivity to variants like omicron. Antigen tests already include presumptive negative labeling and must detect known variants. Updates will be shared as new data emerges.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: FDA is not anticipating modifying the performance recommendations for antigen tests. Particularly as the use of rapid antigen tests increases, it's important that these tests are able to detect known variants, including omicron. Antigen tests are already labeled with a presumptive negative claim given the lower PPA than most molecular tests, and we do not anticipate reducing that performance recommendation any further. As additional information becomes available about the impact of omicron or future variants on diagnostic tests, we will continue to update the website with this information. And we do have a specific SARS-CoV-2 viral mutations impact on COVID-19 tests website that we update regularly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antigen test sensitivity, Variants like omicron, FDA performance recommendations
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Where can test developers find updates on the impact of SARS-CoV-2 variants on diagnostic test performance?
CLARIFIED ANSWER: Test developers can find updates on the impact of SARS-CoV-2 variants on the FDA's website dedicated to SARS-CoV-2 viral mutations and their impact on COVID-19 tests.
VERBATIM QUESTION: Where can test developers find updates on the impact of SARS-CoV-2 variants on diagnostic test performance?
VERBATIM ANSWER: As additional information becomes available about the impact of omicron or future variants on diagnostic tests, we will continue to update the website with this information. And we do have a specific SARS-CoV-2 viral mutations impact on COVID-19 tests website that we update regularly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 variants, Diagnostic test updates, FDA resources
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Why do antigen tests carry a presumptive negative claim compared to molecular tests?
CLARIFIED ANSWER: Antigen tests have a presumptive negative claim due to their lower PPA compared to molecular tests.
VERBATIM QUESTION: Why do antigen tests carry a presumptive negative claim compared to molecular tests?
VERBATIM ANSWER: Antigen tests are already labeled with a presumptive negative claim given the lower PPA than most molecular tests, and we do not anticipate reducing that performance recommendation any further.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antigen test sensitivity, performance differences, molecular tests
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: How frequently is the FDA's SARS-CoV-2 viral mutations impact website updated?
CLARIFIED ANSWER: The FDA regularly updates its SARS-CoV-2 viral mutations impact on COVID-19 tests website.
VERBATIM QUESTION: How frequently is the FDA's SARS-CoV-2 viral mutations impact website updated?
VERBATIM ANSWER: We do have a specific SARS-CoV-2 viral mutations impact on COVID-19 tests website that we update regularly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 mutations, FDA website updates, COVID-19 diagnostics
REVIEW FLAG: False


#### 8. FDA Guidance on Multi-Analyte Test Emergency Use Authorizations

QA Block 8-1
CLARIFIED QUESTION: Is FDA still considering emergency use authorizations for multi-analyte over-the-counter tests?
CLARIFIED ANSWER: FDA recommends developers interested in pursuing EUAs for over-the-counter multi-analyte tests submit a pre-EUA to discuss their proposals.
VERBATIM QUESTION: Is FDA still considering emergency use authorizations for multi-analyte over-the-counter tests?
VERBATIM ANSWER: Yes, the FDA continues to recommend that developers interested in pursuing an EUA for an over-the-counter multi-analyte test to submit a pre-EUA to further discuss your proposal.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multi-analyte tests, emergency use authorization, pre-EUA submission
REVIEW FLAG: False


#### 9. CT Value Requirements and Omicron Sequencing for SARS-CoV-2 Tests

QA Block 9-1
CLARIFIED QUESTION: Is there a cutoff for the CT values for the data to present?
CLARIFIED ANSWER: The FDA requires CT results for all clinical samples and specifies not excluding data. A certain number of low positives, defined in the template, are required. CT values are used to determine these. Ensure the comparator molecular test is highly sensitive and check with the FDA before use.
VERBATIM QUESTION: Is there a cutoff for the CT values for the data to present?
VERBATIM ANSWER: OK. Yeah, so we want CT results for all of your clinical samples. See our antigen templates on the FDA website. And we want to see all the data. We don't want any data excluded. And we want to see a certain number of low positives, which are defined in the template about what low positives are. And we use CTs to do that. And we want your comparator molecular test to be an acceptable high sensitivity one, so do check with the FDA prior to using that test.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CT value requirements, Clinical sample data, Comparator test sensitivity
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Do the patient samples need to be sequenced to confirm the omicron strain, or how would you verify that the strain is present?
CLARIFIED ANSWER: Sequence confirmation for the omicron strain is eventually required. For new clinical studies, all clinical samples should be sequenced. Since omicron is currently dominant in the US, ongoing studies are likely omicron, with sequencing used for confirmation. Those with completed studies should coordinate with their reviewer to meet specific requirements.
VERBATIM QUESTION: Do the patient samples need to be sequenced to confirm the omicron strain, or how would you verify that the strain is present?
VERBATIM ANSWER: Eventually we'll want-- Yeah, eventually we want sequence confirmation, but it depends on the situation. So if you've not done your clinical study yet, yes, go ahead and sequence your clinical study samples. Omicron, last time I looked, was about 99% or greater in the US. So any study that's done right now is going to most likely be omicron, and the sequencing will confirm it. Just make sure the sequencing method has been validated in some way. If somebody is already in with a submission and we're now asking for omicron information, they should work that out with their lead reviewer about the number of samples we want to see because they may have already completed a study with delta and the other information we need about those samples prior to making an authorization decision.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: omicron strain confirmation, clinical sample sequencing, data submission requirements
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: How do we show that we have omicron data?
CLARIFIED ANSWER: FDA recommends sequencing clinical study samples to confirm the Omicron variant, considering it is highly prevalent. If the clinical study is already submitted, developers should coordinate with their lead reviewer to address requirements for Omicron data.
VERBATIM QUESTION: How do we show that we have omicron data?
VERBATIM ANSWER: Eventually we'll want-- Yeah, eventually we want sequence confirmation, but it depends on the situation. So if you've not done your clinical study yet, yes, go ahead and sequence your clinical study samples. Omicron, last time I looked, was about 99% or greater in the US. So any study that's done right now is going to most likely be omicron, and the sequencing will confirm it. Just make sure the sequencing method has been validated in some way. If somebody is already in with a submission and we're now asking for omicron information, they should work that out with their lead reviewer about the number of samples we want to see because they may have already completed a study with delta and the other information we need about those samples prior to making an authorization decision.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Omicron data sequencing, Clinical study submission, Variant confirmation
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: What specific data is required to define low positives for an antigen SARS-CoV-2 test?
CLARIFIED ANSWER: The FDA requires CT results for all clinical samples, full data inclusion, and a defined number of low positives per the antigen template. CT values are used to identify low positives. The comparator molecular test should have high sensitivity and be pre-approved by FDA.
VERBATIM QUESTION: What specific data is required to define low positives for an antigen SARS-CoV-2 test?
VERBATIM ANSWER: OK. Yeah, so we want CT results for all of your clinical samples. See our antigen templates on the FDA website. And we want to see all the data. We don't want any data excluded. And we want to see a certain number of low positives, which are defined in the template about what low positives are. And we use CTs to do that. And we want your comparator molecular test to be an acceptable high sensitivity one, so do check with the FDA prior to using that test.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test data requirements, Low positives definition, Clinical sample data inclusion
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Where can developers find detailed guidelines for submitting CT value data for antigen tests?
CLARIFIED ANSWER: Refer to the antigen test templates on the FDA website for detailed guidelines on submitting CT value data.
VERBATIM QUESTION: Where can developers find detailed guidelines for submitting CT value data for antigen tests?
VERBATIM ANSWER: Yeah, so we want CT results for all of your clinical samples. See our antigen templates on the FDA website. And we want to see all the data. We don't want any data excluded. And we want to see a certain number of low positives, which are defined in the template about what low positives are. And we use CTs to do that. And we want your comparator molecular test to be an acceptable high sensitivity one, so do check with the FDA prior to using that test.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CT value data submission, antigen tests, FDA guidelines
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: What criteria must the comparator molecular test meet to be considered an acceptable high sensitivity test?
CLARIFIED ANSWER: The comparator molecular test must meet high sensitivity standards, and FDA approval should be sought prior to its use.
VERBATIM QUESTION: What criteria must the comparator molecular test meet to be considered an acceptable high sensitivity test?
VERBATIM ANSWER: And we want your comparator molecular test to be an acceptable high sensitivity one, so do check with the FDA prior to using that test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator molecular test, high sensitivity criteria, FDA consultation
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: What steps should be taken if a clinical study has already been completed with a different strain (e.g., delta) but additional omicron data is now required?
CLARIFIED ANSWER: If a clinical study was completed with a different strain like delta, applicants must coordinate with their FDA lead reviewer to determine the number of omicron samples needed and provide the required information for authorization.
VERBATIM QUESTION: What steps should be taken if a clinical study has already been completed with a different strain (e.g., delta) but additional omicron data is now required?
VERBATIM ANSWER: If somebody is already in with a submission and we're now asking for omicron information, they should work that out with their lead reviewer about the number of samples we want to see because they may have already completed a study with delta and the other information we need about those samples prior to making an authorization decision.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Clinical study strain updates, Omicron data requirements for FDA
REVIEW FLAG: False


#### 10. Sequencing Confirmation Required for Positive Clinical Trial Samples

QA Block 10-1
CLARIFIED QUESTION: If we just start a clinical trial, do we need to confirm any sequence for omicron?
CLARIFIED ANSWER: Yes, sequence analysis is required to confirm omicron, as delta may still be circulating in some areas.
VERBATIM QUESTION: If we just start a clinical trial, do we need to confirm any sequence for omicron?
VERBATIM ANSWER: Yes, please do. If you haven't started your trial, clinical study yet, please go ahead and plan to do the sequence analysis. There is delta circulating in some areas and some pockets in the United States, and you just may have hit a pocket that has more delta than others. So it's important for us to know that it's omicron.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sequence confirmation, omicron versus delta, clinical trials
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: For all positive samples in a clinical study, do you need sequencing confirmation?
CLARIFIED ANSWER: FDA requires sequencing confirmation for all positive samples in a clinical study.
VERBATIM QUESTION: For all positive samples in a clinical study, do you need sequencing confirmation?
VERBATIM ANSWER: All the positive samples.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sequencing confirmation, positive samples, clinical study
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Why is sequencing analysis necessary for clinical trials even if omicron is the dominant variant?
CLARIFIED ANSWER: Sequencing analysis is necessary to confirm that samples are omicron, as delta may still be circulating in some U.S. regions.
VERBATIM QUESTION: Why is sequencing analysis necessary for clinical trials even if omicron is the dominant variant?
VERBATIM ANSWER: Yes, please do. If you haven't started your trial, clinical study yet, please go ahead and plan to do the sequence analysis. There is delta circulating in some areas and some pockets in the United States, and you just may have hit a pocket that has more delta than others. So it's important for us to know that it's omicron.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sequencing analysis in clinical trials, omicron and delta variants
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Under what circumstances might delta variants still be present during a clinical trial in the United States?
CLARIFIED ANSWER: Delta variants might still be present in some areas of the United States where they are circulating in localized pockets, which could affect clinical trials.
VERBATIM QUESTION: Under what circumstances might delta variants still be present during a clinical trial in the United States?
VERBATIM ANSWER: There is delta circulating in some areas and some pockets in the United States, and you just may have hit a pocket that has more delta than others. So it's important for us to know that it's omicron.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Delta variant presence, Clinical trials, Sequencing for variants
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What steps should be taken if a clinical trial encounters a higher proportion of delta cases than expected?
CLARIFIED ANSWER: FDA advises performing sequence analysis during the clinical trial to confirm omicron even if delta cases are unexpectedly present in some areas.
VERBATIM QUESTION: What steps should be taken if a clinical trial encounters a higher proportion of delta cases than expected?
VERBATIM ANSWER: If you haven't started your trial, clinical study yet, please go ahead and plan to do the sequence analysis. There is delta circulating in some areas and some pockets in the United States, and you just may have hit a pocket that has more delta than others. So it's important for us to know that it's omicron.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical trial sequencing, omicron vs delta, sample analysis
REVIEW FLAG: False


#### 11. FDA Guidance on New Lab Testing Authorizations

QA Block 11-1
CLARIFIED QUESTION: Do we have to submit for EUA or can we proceed as an LDT when starting a small RT-PCR based lab?
CLARIFIED ANSWER: Yes, labs starting new RT-PCR-based tests, including LDTs, must submit for EUA authorization and have full authorization before beginning testing, as outlined in FDA guidance from November 15, 2021.
VERBATIM QUESTION: Do we have to submit for EUA or can we proceed as an LDT when starting a small RT-PCR based lab?
VERBATIM ANSWER: Well, see the November 15, 2021 guidance and see how it will apply to you. There are hundreds of molecular test opportunities, and there is no shortage of all molecular kits that are available for use in a lab. And so we do encourage those. If someone wants to pursue an LDT, look to the guidance. But now, the FDA is saying that a submission is needed if it hasn't already been made under the guidance. Yeah, I would just add since you specified that you're starting a new lab, that leads me to believe that you're not-- haven't begun testing. So for any new tests, including LDTs, and this is spelled out in the guidance that Tim is referencing, and we do expect an authorization, fully authorized and not just submitted an EUA request prior to testing.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission requirement, LDTs for new labs, FDA guidance
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Even if the test is conducted only to scale up testing and involves only 100 samples a day, does authorization still apply?
CLARIFIED ANSWER: FDA requires new tests, including those for low-volume testing, to meet volume minimums for EUA review unless the test was validated before November 15, 2021. Low-volume testing can proceed using authorized manufactured kits.
VERBATIM QUESTION: Even if the test is conducted only to scale up testing and involves only 100 samples a day, does authorization still apply?
VERBATIM ANSWER: Yes, and so if you're only going to do 100 tests a day, it's unlikely to meet our volume expectations for review, and therefore, an EUA would not-- that your submission wouldn't be reviewed due to low volume testing. This doesn't apply to any tests that were already validated by November 15, 2021. We are not applying any volume metrics to that. It was on the market. We wanted to facilitate it staying on the market. But any new tests that come in after the guidance will need to-- of any type, whether it's manufactured kits or LDTs, will need to meet the volume minimums in order to substantially increase the amount of testing that's performed in the United States. Those are the guidelines. That's the policy.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, low-volume testing, FDA guidance
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: Can new lab setups offer low volume testing without EUA authorization?
CLARIFIED ANSWER: New labs can offer low volume testing, but they must use authorized manufactured kits and cannot offer it as an LDT without EUA authorization.
VERBATIM QUESTION: Can new lab setups offer low volume testing without EUA authorization?
VERBATIM ANSWER: Yes, they can. They can offer. They can absolutely offer low volume testing. They just need to go ahead and purchase one of the manufactured kits that's been authorized.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low volume testing, EUA requirements, manufactured kits
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What are the requirements for tests validated before November 15, 2021, in terms of volume metrics?
CLARIFIED ANSWER: Tests validated before November 15, 2021, are not subject to volume metrics as long as they were already on the market.
VERBATIM QUESTION: What are the requirements for tests validated before November 15, 2021, in terms of volume metrics?
VERBATIM ANSWER: This doesn't apply to any tests that were already validated by November 15, 2021. We are not applying any volume metrics to that. It was on the market. We wanted to facilitate it staying on the market.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: volume metrics, tests validated before November 15, 2021
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: Can low volume testing be performed with an FDA-authorized manufactured kit if not using an LDT?
CLARIFIED ANSWER: Low volume testing can be performed using an FDA-authorized manufactured kit, but not as an LDT.
VERBATIM QUESTION: Can low volume testing be performed with an FDA-authorized manufactured kit if not using an LDT?
VERBATIM ANSWER: Yes, they can. They can offer. They can absolutely offer low volume testing. They just need to go ahead and purchase one of the manufactured kits that's been authorized.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Low volume testing, FDA-authorized kits, LDT restrictions
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: Does the FDA require a fully authorized EUA prior to any new testing, including LDTs?
CLARIFIED ANSWER: FDA requires a fully authorized EUA, not just a submission, for any new tests, including LDTs, before testing can begin.
VERBATIM QUESTION: Does the FDA require a fully authorized EUA prior to any new testing, including LDTs?
VERBATIM ANSWER: Yeah, I would just add since you specified that you're starting a new lab, that leads me to believe that you're not-- haven't begun testing. So for any new tests, including LDTs, and this is spelled out in the guidance that Tim is referencing, and we do expect an authorization, fully authorized and not just submitted an EUA request prior to testing.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements, LDT policies, New testing authorization
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: What is the volume minimum requirement that new tests must meet to substantially increase testing in the U.S.?
CLARIFIED ANSWER: FDA requires new tests to meet volume minimums to substantially increase U.S. testing. Tests like 100 samples/day may not qualify for EUA review. Volume requirements don't apply to tests validated before November 15, 2021.
VERBATIM QUESTION: What is the volume minimum requirement that new tests must meet to substantially increase testing in the U.S.?
VERBATIM ANSWER: Yes, and so if you're only going to do 100 tests a day, it's unlikely to meet our volume expectations for review, and therefore, an EUA would not-- that your submission wouldn't be reviewed due to low volume testing. This doesn't apply to any tests that were already validated by November 15, 2021. We are not applying any volume metrics to that. It was on the market. We wanted to facilitate it staying on the market. But any new tests that come in after the guidance will need to-- of any type, whether it's manufactured kits or LDTs, will need to meet the volume minimums in order to substantially increase the amount of testing that's performed in the United States. Those are the guidelines. That's the policy.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Volume requirements, EUA submission, New diagnostic tests
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: Does the guidance apply to both manufactured kits and LDTs for new submissions?
CLARIFIED ANSWER: The guidance applies to both manufactured kits and LDTs for new submissions, which must meet volume minimums to support increased testing.
VERBATIM QUESTION: Does the guidance apply to both manufactured kits and LDTs for new submissions?
VERBATIM ANSWER: But any new tests that come in after the guidance will need to-- of any type, whether it's manufactured kits or LDTs, will need to meet the volume minimums in order to substantially increase the amount of testing that's performed in the United States. Those are the guidelines. That's the policy.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: guidance applicability, manufactured kits, LDTs
REVIEW FLAG: False


#### 12. Guidelines for Asymptomatic Testing and Specimen Use in Trials

QA Block 12-1
CLARIFIED QUESTION: Would data based on leftover specimens be potentially transferable into 510k?
CLARIFIED ANSWER: FDA advises reviewing the molecular testing templates to determine whether data using leftover specimens may be transferable to a 510(k), as this depends on how the specimens are collected.
VERBATIM QUESTION: Would data based on leftover specimens be potentially transferable into 510k?
VERBATIM ANSWER: I think I'd look at the template for asymptomatics because there's couple of options there. And you were talking about leftover samples, then it depends on how they're collected. So all that is outlined in the molecular-- sorry, molecular template. Excuse me.
SPEAKER QUESTION: Vitali Karaliou
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: leftover specimens, 510(k) transferability, molecular template
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Do you have any comments on the inclusion of asymptomatic patient populations into this kind of study?
CLARIFIED ANSWER: The FDA suggests reviewing current templates on its website for guidance and advises that data from asymptomatic individuals would be needed for authorization of asymptomatic testing.
VERBATIM QUESTION: Do you have any comments on the inclusion of asymptomatic patient populations into this kind of study?
VERBATIM ANSWER: Yeah, if you want to include asymptomatics, check the current templates on the FDA website. There are a number of different possibilities that you can propose. But we would want to see the actual data in asymptomatic individuals in order to make an authorization for asymptomatic testing.
SPEAKER QUESTION: Vitali Karaliou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, FDA templates, clinical study design
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What data or documentation would be required to demonstrate the validity of asymptomatic testing for EUAs?
CLARIFIED ANSWER: For asymptomatic testing under EUAs, the FDA requires actual data from asymptomatic individuals and advises checking the current templates on the FDA website to explore the available options.
VERBATIM QUESTION: What data or documentation would be required to demonstrate the validity of asymptomatic testing for EUAs?
VERBATIM ANSWER: Yeah, if you want to include asymptomatics, check the current templates on the FDA website. There are a number of different possibilities that you can propose. But we would want to see the actual data in asymptomatic individuals in order to make an authorization for asymptomatic testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, EUA requirements, data submission
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: How does the FDA define proper collection methods when using leftover samples for testing?
CLARIFIED ANSWER: The FDA advises referring to the molecular template for guidelines on proper collection methods for leftover samples, as it depends on how they are collected.
VERBATIM QUESTION: How does the FDA define proper collection methods when using leftover samples for testing?
VERBATIM ANSWER: I think I'd look at the template for asymptomatics because there's couple of options there. And you were talking about leftover samples, then it depends on how they're collected. So all that is outlined in the molecular-- sorry, molecular template. Excuse me.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: leftover sample collection, molecular template, FDA guidance
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: What are the acceptable limitations for including symptomatic individuals in clinical studies?
CLARIFIED ANSWER: FDA states that symptomatic individuals can be included in clinical studies, but testing should be limited to individuals who have been symptomatic for no more than 14 days. Further guidance can be found in other molecular authorizations.
VERBATIM QUESTION: What are the acceptable limitations for including symptomatic individuals in clinical studies?
VERBATIM ANSWER: Well, symptomatic's very straightforward. You test symptomatics. You probably want to limit how many days they've been symptomatic, and you don't want to probably go beyond 14 days. And you can look at other molecular authorizations. Toby, Kris, any additional thoughts? I think that means we're good.
SPEAKER QUESTION: Vitali Karaliou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Inclusion of symptomatic individuals, Clinical study limitations
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Does the specific method of collecting leftover specimens impact their suitability for studies on asymptomatic testing?
CLARIFIED ANSWER: The suitability of leftover specimens for studies on asymptomatic testing depends on how they are collected and is addressed in FDA's molecular template.
VERBATIM QUESTION: Does the specific method of collecting leftover specimens impact their suitability for studies on asymptomatic testing?
VERBATIM ANSWER: I think I'd look at the template for asymptomatics because there's couple of options there. And you were talking about leftover samples, then it depends on how they're collected. So all that is outlined in the molecular-- sorry, molecular template. Excuse me.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Leftover specimen collection, Asymptomatic testing, FDA molecular template
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Are there templates or guidance documents detailing options for designing asymptomatic testing studies?
CLARIFIED ANSWER: FDA advises checking the templates on its website, which outline various options for designing asymptomatic testing studies, but emphasizes the need for data from asymptomatic individuals for authorization.
VERBATIM QUESTION: Are there templates or guidance documents detailing options for designing asymptomatic testing studies?
VERBATIM ANSWER: If you want to include asymptomatics, check the current templates on the FDA website. There are a number of different possibilities that you can propose. But we would want to see the actual data in asymptomatic individuals in order to make an authorization for asymptomatic testing.
SPEAKER QUESTION: Vitali Karaliou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, FDA templates, study design
REVIEW FLAG: False


#### 13. In Silico Analysis Versus Clinical Testing for Omicron Detection

QA Block 13-1
CLARIFIED QUESTION: Is in silico analysis sufficient for a nucleocapsid test for the omicron variant, or is it necessary to include samples from omicron patients as well?
CLARIFIED ANSWER: In silico analysis is sufficient for molecular nucleocapsid tests for the omicron variant; actual patient samples are only required for antigen tests. FDA will address any concerns with test developers directly.
VERBATIM QUESTION: Is in silico analysis sufficient for a nucleocapsid test for the omicron variant, or is it necessary to include samples from omicron patients as well?
VERBATIM ANSWER: Yes, but thank you for that question and the opportunity to clarify. The actual patient sample testing with omicron is only going to be needed for antigen tests. The molecular tests can be used. The in silico analysis can be used for the molecular test. If the FDA review team has any concern about any variants and mutations in the in silico analysis, they will discuss that directly with the test developer. So yeah, my remarks regarding omicron and the need to see clinical samples is only for antigen tests.
SPEAKER QUESTION: Jiayan Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: in silico analysis, omicron patient samples, antigen vs. molecular tests
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Are omicron-specific clinical sample tests required for sequencing assays?
CLARIFIED ANSWER: Omicron-specific clinical sample testing is not needed for sequencing assays unless there is an identified issue requiring further investigation.
VERBATIM QUESTION: Are omicron-specific clinical sample tests required for sequencing assays?
VERBATIM ANSWER: And the same-- yep, and the same thing goes for sequencing of samples. For the molecular tests, we don't need to know if they're Omicron or not unless there is some issue we need to look into. Thanks.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sequencing assays, omicron testing requirements, molecular tests
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: What are the FDA's actions if concerns arise regarding variants or mutations during in silico analysis for molecular tests?
CLARIFIED ANSWER: The FDA will directly discuss any concerns about variants or mutations identified during in silico analysis with the test developer.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: If the FDA review team has any concern about any variants and mutations in the in silico analysis, they will discuss that directly with the test developer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: variants impact on molecular tests, FDA review process
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Is FDA review required for molecular tests that do not rely on omicron patient samples?
CLARIFIED ANSWER: Clinical samples from omicron patients are only required for antigen tests, not molecular tests. In silico analysis can be used for molecular tests, and any concerns with variants will be addressed directly by the FDA with the developer.
VERBATIM QUESTION: Is FDA review required for molecular tests that do not rely on omicron patient samples?
VERBATIM ANSWER: Yes, but thank you for that question and the opportunity to clarify. The actual patient sample testing with omicron is only going to be needed for antigen tests. The molecular tests can be used. The in silico analysis can be used for the molecular test. If the FDA review team has any concern about any variants and mutations in the in silico analysis, they will discuss that directly with the test developer. So yeah, my remarks regarding omicron and the need to see clinical samples is only for antigen tests.
SPEAKER QUESTION: Jiayan Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: molecular test requirements, omicron variant, in silico analysis
REVIEW FLAG: False


#### 14. Guidance on Shipping Stability for EUA Submissions

QA Block 14-1
CLARIFIED QUESTION: Does the FDA have specific guidance or recommendations on which distribution simulation standards should be followed for a shipping stability study for molecular diagnostic tests?
CLARIFIED ANSWER: FDA suggests checking the molecular diagnostic templates or contacting the Templates email box for guidance. Proposed standards like ASTM are welcomed if appropriate.
VERBATIM QUESTION: Does the FDA have specific guidance or recommendations on which distribution simulation standards should be followed for a shipping stability study for molecular diagnostic tests?
VERBATIM ANSWER: Yes, if it's not in the templates, we can provide that. Kris, I'll turn it over to you as well here. You can probably just email the Templates email box and get a pretty quick response, or put it in a pre-EUA, if you're putting in a pre-EUA, though I don't necessarily recommend a pre-EUA for this. But Kris, do you have some more helpful comments than mine perhaps? No, I think that's the best route to go. We're open to using any ASTM standard that may be widely applicable. And so, if you have an idea of what you want to follow or what you think is appropriate, then you can go ahead and propose that to us as well.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: distribution simulation standards, shipping stability studies, molecular diagnostic tests
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Is it necessary to include shipping stability data in a full EUA submission, or could it be provided during or after the process?
CLARIFIED ANSWER: FDA recommends starting the shipping stability studies, and if incomplete by review time, discussing mitigation strategies, such as dry ice shipping, with the team.
VERBATIM QUESTION: Is it necessary to include shipping stability data in a full EUA submission, or could it be provided during or after the process?
VERBATIM ANSWER: We would recommend that you begin it, and then, if it's not completed by the time it's time to make a review decision, have a conversation with the team. There could be certain things that can impact that in fact. So for example, if a molecular kit is shipped on dry ice and it's required to be received on dry ice, that would be a potential mitigation for heating and cooling during shipping.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: shipping stability data, EUA requirements, mitigation strategies
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: Can developers propose an alternative ASTM shipping stability standard to the FDA if they believe it is more appropriate?
CLARIFIED ANSWER: The FDA is open to accepting any ASTM standard that is widely applicable. Developers can propose a standard they believe is appropriate for use.
VERBATIM QUESTION: Can developers propose an alternative ASTM shipping stability standard to the FDA if they believe it is more appropriate?
VERBATIM ANSWER: No, I think that's the best route to go. We're open to using any ASTM standard that may be widely applicable. And so, if you have an idea of what you want to follow or what you think is appropriate, then you can go ahead and propose that to us as well.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: ASTM standards, shipping stability, EUA submissions
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: In what circumstances could a discussion with the FDA team about incomplete shipping stability data influence the review process?
CLARIFIED ANSWER: FDA recommends starting shipping stability studies and discussing incomplete data with the team if the studies are not finished by the time of the review decision. For instance, dry ice shipping could mitigate temperature issues.
VERBATIM QUESTION: In what circumstances could a discussion with the FDA team about incomplete shipping stability data influence the review process?
VERBATIM ANSWER: We would recommend that you begin it, and then, if it's not completed by the time it's time to make a review decision, have a conversation with the team. There could be certain things that can impact that in fact. So for example, if a molecular kit is shipped on dry ice and it's required to be received on dry ice, that would be a potential mitigation for heating and cooling during shipping.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: shipping stability, EUA submission, regulatory discussion
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: Does the requirement to use dry ice for shipping serve as mitigation for temperature variations during transport?
CLARIFIED ANSWER: Using dry ice for shipping can help mitigate temperature fluctuations during transport if the kit is required to be received on dry ice.
VERBATIM QUESTION: Does the requirement to use dry ice for shipping serve as mitigation for temperature variations during transport?
VERBATIM ANSWER: For example, if a molecular kit is shipped on dry ice and it's required to be received on dry ice, that would be a potential mitigation for heating and cooling during shipping.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Shipping conditions, Temperature mitigation, Dry ice use
REVIEW FLAG: False


#### 15. FDA Guidance on Notified Test Kits Distribution

QA Block 15-1
CLARIFIED QUESTION: With the recent change in the guidance, do new high complexity CLIA labs performing validation to run our kit make it be considered an LDT under FDA regulation, thus requiring them to submit and await approval of their EUA to run that test?
CLARIFIED ANSWER: Under the November 15 guidance, high complexity CLIA labs using your test kit can continue operations as a notified test kit without submitting anything to the FDA, provided your EUA is actively under review.
VERBATIM QUESTION: With the recent change in the guidance, do new high complexity CLIA labs performing validation to run our kit make it be considered an LDT under FDA regulation, thus requiring them to submit and await approval of their EUA to run that test?
VERBATIM ANSWER: OK, then under the November 15 policy, as long as you have-- as long as your submission was either after, I think it was February of 2021 or before that, if you've let us know that you want us to continue to review so your submission is actively under review, then you can continue to distribute your test to high complexity CLIA certified labs-- excuse me. And they can continue to perform it as a notified test kit under that continued distribution during FDA review policy. That's laid out in the November 15 guidance. We do not expect those labs that are using your test kit to submit anything to FDA.
SPEAKER QUESTION: Josh Profeto
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA lab validation, LDT and FDA requirements, November 15 guidance
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Can it continue as before the change?
CLARIFIED ANSWER: Yes, under the November 15 policy, if the EUA submission is actively under review, the test can continue to be distributed and performed as a notified test kit, and labs do not need to submit anything to the FDA.
VERBATIM QUESTION: Can it continue as before the change?
VERBATIM ANSWER: OK, then under the November 15 policy, as long as you have-- as long as your submission was either after, I think it was February of 2021 or before that, if you've let us know that you want us to continue to review so your submission is actively under review, then you can continue to distribute your test to high complexity CLIA certified labs-- excuse me. And they can continue to perform it as a notified test kit under that continued distribution during FDA review policy. That's laid out in the November 15 guidance. We do not expect those labs that are using your test kit to submit anything to FDA.
SPEAKER QUESTION: Josh Profeto
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission, FDA notification policy, CLIA lab testing
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: What additional validation do high complexity CLIA labs need to perform for tests that are not yet FDA authorized?
CLARIFIED ANSWER: High complexity CLIA labs do not need to submit anything to the FDA for tests under the notification policy as long as the submission for review remains active under the November 15 policy.
VERBATIM QUESTION: What additional validation do high complexity CLIA labs need to perform for tests that are not yet FDA authorized?
VERBATIM ANSWER: OK, then under the November 15 policy, as long as you have-- as long as your submission was either after, I think it was February of 2021 or before that, if you've let us know that you want us to continue to review so your submission is actively under review, then you can continue to distribute your test to high complexity CLIA certified labs-- excuse me. And they can continue to perform it as a notified test kit under that continued distribution during FDA review policy. That's laid out in the November 15 guidance. We do not expect those labs that are using your test kit to submit anything to FDA.
SPEAKER QUESTION: Josh Profeto
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: validation requirements, high complexity CLIA labs, FDA notification policy
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: Under the November 15 guidance, can developers with an actively under-review EUA submission continue distributing their test kits?
CLARIFIED ANSWER: Under the November 15 guidance, developers with an active EUA under review can continue distributing test kits to high complexity CLIA labs as notified kits. Such labs do not need to submit anything to FDA.
VERBATIM QUESTION: Under the November 15 guidance, can developers with an actively under-review EUA submission continue distributing their test kits?
VERBATIM ANSWER: OK, then under the November 15 policy, as long as you have-- as long as your submission was either after, I think it was February of 2021 or before that, if you've let us know that you want us to continue to review so your submission is actively under review, then you can continue to distribute your test to high complexity CLIA certified labs-- excuse me. And they can continue to perform it as a notified test kit under that continued distribution during FDA review policy. That's laid out in the November 15 guidance. We do not expect those labs that are using your test kit to submit anything to FDA.
SPEAKER QUESTION: Josh Profeto
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: November 15 guidance, EUA submission, CLIA lab testing
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: Can high complexity CLIA labs use test kits under the notification policy without submitting documentation to the FDA?
CLARIFIED ANSWER: High complexity CLIA labs can continue to use notified test kits under the policy, provided the test distributor's EUA submission is actively under review, and labs do not need to submit documentation to the FDA.
VERBATIM QUESTION: Can high complexity CLIA labs use test kits under the notification policy without submitting documentation to the FDA?
VERBATIM ANSWER: OK, then under the November 15 policy, as long as you have-- as long as your submission was either after, I think it was February of 2021 or before that, if you've let us know that you want us to continue to review so your submission is actively under review, then you can continue to distribute your test to high complexity CLIA certified labs-- excuse me. And they can continue to perform it as a notified test kit under that continued distribution during FDA review policy. That's laid out in the November 15 guidance. We do not expect those labs that are using your test kit to submit anything to FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Test kit notification policy, High complexity CLIA labs, FDA documentation requirements
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: Where can developers find written documentation or FAQs related to notification policies and test kit distribution?
CLARIFIED ANSWER: FDA documentation about notification policies and test kit distribution can be found in a question on the FAQ page, which is included on the page with the notification list.
VERBATIM QUESTION: Where can developers find written documentation or FAQs related to notification policies and test kit distribution?
VERBATIM ANSWER: We do have a question on our FAQ page. It's on the page that includes the notification list. We do have a question that addresses that, as well, if you want something in writing to share with the lab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Notification policies, FAQ page, Test kit distribution
REVIEW FLAG: False


#### 16. EUA Authorized Tests and Market Purchase Guidelines

QA Block 16-1
CLARIFIED QUESTION: Is the labeling issue with ACON tests legally resolved?
CLARIFIED ANSWER: FDA advises that any EUA-authorized test, including ACON tests, can be purchased. To ensure authenticity, buyers should verify that they are purchasing EUA-authorized versions and can check directly with the manufacturer.
VERBATIM QUESTION: Is the labeling issue with ACON tests legally resolved?
VERBATIM ANSWER: So any EUA authorized test can be purchased. If you have any question about the authenticity of any test, there are situations out there that all labs should be cautious about. For example, there are many tests that have CE marked versions that have not been reviewed by the FDA. And it's important that users in the United States only get the EUA authorized version. If you have any questions, you can always contact each individual manufacturer and make sure that the tests that you're about to purchase are legitimate, bona fide, and EUA authorized versions of their tests.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA-authorized diagnostics, ACON test labeling, Test authenticity
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Can the ACON test be purchased in the market right now?
CLARIFIED ANSWER: Any EUA-authorized test, including those from ACON, can be purchased. Users should ensure they are obtaining the legitimate EUA-authorized versions and confirm authenticity with manufacturers if needed.
VERBATIM QUESTION: Can the ACON test be purchased in the market right now?
VERBATIM ANSWER: So any EUA authorized test can be purchased. If you have any question about the authenticity of any test, there are situations out there that all labs should be cautious about. For example, there are many tests that have CE marked versions that have not been reviewed by the FDA. And it's important that users in the United States only get the EUA authorized version. If you have any questions, you can always contact each individual manufacturer and make sure that the tests that you're about to purchase are legitimate, bona fide, and EUA authorized versions of their tests.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorized tests, market availability, test authenticity
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: What precautions should be taken to avoid purchasing COVID-19 tests that are not EUA authorized?
CLARIFIED ANSWER: Consumers should verify that the COVID-19 tests they purchase are EUA authorized, as some tests with CE marks have not been reviewed by the FDA. Contact the manufacturer to confirm authenticity and ensure the tests are genuine and authorized.
VERBATIM QUESTION: What precautions should be taken to avoid purchasing COVID-19 tests that are not EUA authorized?
VERBATIM ANSWER: Any EUA authorized test can be purchased. If you have any question about the authenticity of any test, there are situations out there that all labs should be cautious about. For example, there are many tests that have CE marked versions that have not been reviewed by the FDA. And it's important that users in the United States only get the EUA authorized version. If you have any questions, you can always contact each individual manufacturer and make sure that the tests that you're about to purchase are legitimate, bona fide, and EUA authorized versions of their tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, Test authenticity, Purchasing precautions
REVIEW FLAG: False

QA Block 16-4
CLARIFIED QUESTION: Are there certain identifiers or methods to verify that a COVID-19 test is indeed EUA authorized?
CLARIFIED ANSWER: To verify that a test is EUA authorized, ensure it's intended for the U.S. market, as some CE marked tests have not been FDA-reviewed. Users should contact the manufacturer to confirm the test is legitimate and authorized.
VERBATIM QUESTION: Are there certain identifiers or methods to verify that a COVID-19 test is indeed EUA authorized?
VERBATIM ANSWER: If you have any question about the authenticity of any test, there are situations out there that all labs should be cautious about. For example, there are many tests that have CE marked versions that have not been reviewed by the FDA. And it's important that users in the United States only get the EUA authorized version. If you have any questions, you can always contact each individual manufacturer and make sure that the tests that you're about to purchase are legitimate, bona fide, and EUA authorized versions of their tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, test authenticity, manufacturer verification
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: Why should users in the United States avoid tests with CE marking that have not been reviewed by the FDA?
CLARIFIED ANSWER: Users in the United States should only purchase EUA-authorized tests because CE-marked tests may not have been reviewed by the FDA.
VERBATIM QUESTION: Why should users in the United States avoid tests with CE marking that have not been reviewed by the FDA?
VERBATIM ANSWER: For example, there are many tests that have CE marked versions that have not been reviewed by the FDA. And it's important that users in the United States only get the EUA authorized version.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CE-marked tests, FDA review, EUA authorization
REVIEW FLAG: False

QA Block 16-6
CLARIFIED QUESTION: Is contacting the manufacturer the recommended procedure for verifying authenticity of COVID-19 tests?
CLARIFIED ANSWER: Yes, contacting the manufacturer is recommended to verify the authenticity and ensure tests are genuine and EUA authorized.
VERBATIM QUESTION: Is contacting the manufacturer the recommended procedure for verifying authenticity of COVID-19 tests?
VERBATIM ANSWER: If you have any question about the authenticity of any test, there are situations out there that all labs should be cautious about. For example, there are many tests that have CE marked versions that have not been reviewed by the FDA. And it's important that users in the United States only get the EUA authorized version. If you have any questions, you can always contact each individual manufacturer and make sure that the tests that you're about to purchase are legitimate, bona fide, and EUA authorized versions of their tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test authenticity, EUA authorized tests, manufacturer contact
REVIEW FLAG: False


#### 17. Antigen Test Review Timelines and Submission Guidance

QA Block 17-2
CLARIFIED QUESTION: When should one expect to hear back regarding pre-EUAs and EUAs for antigen tests?
CLARIFIED ANSWER: The FDA recommends limiting pre-EUAs to issues not covered in the template for faster responses. Antigen test submissions are reviewed for completeness, with feedback provided within a few days if incomplete. Once accepted, it becomes a highest priority, but a defined turnaround time cannot be guaranteed due to high submission volumes.
VERBATIM QUESTION: When should one expect to hear back regarding pre-EUAs and EUAs for antigen tests?
VERBATIM ANSWER: So I would recommend restricting pre-EUAs to only questions that aren't covered in the template. Things are pretty clear. And then we can get back to you more quickly. And we do recommend following the FDA recommendations on things because there are a lot of interested parties in this. Once an antigen test is received, it's quickly reviewed for completeness. If it's not complete, we'll get back to you in a few days letting you know it's not complete. But once it's accepted for review, this is the highest priority area within the FDA. And I would personally routinely monitor turnaround times on this and speak to the antigen team to make sure that we move these things along quickly. But unfortunately, we can't promise any defined turnaround time. We are seeing a lot of submissions through the ITAP program and through the RADx program. And so, in addition to other submissions, we are continuing to have a high volume of antigen test submissions.
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA and EUA process, antigen test reviews, submission timelines
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: What types of questions should be restricted to pre-EUAs rather than using the standard templates?
CLARIFIED ANSWER: FDA recommends using pre-EUAs only for questions not covered in the templates to facilitate quicker responses.
VERBATIM QUESTION: What types of questions should be restricted to pre-EUAs rather than using the standard templates?
VERBATIM ANSWER: I would recommend restricting pre-EUAs to only questions that aren't covered in the template. Things are pretty clear. And then we can get back to you more quickly.
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUAs, EUA templates, submission guidelines
REVIEW FLAG: False

QA Block 17-4
CLARIFIED QUESTION: Are there specific recommendations for following the FDA guidance to ensure faster responses?
CLARIFIED ANSWER: FDA recommends restricting pre-EUAs to questions not covered in the template and following FDA guidance to enable faster responses.
VERBATIM QUESTION: Are there specific recommendations for following the FDA guidance to ensure faster responses?
VERBATIM ANSWER: So I would recommend restricting pre-EUAs to only questions that aren't covered in the template. Things are pretty clear. And then we can get back to you more quickly. And we do recommend following the FDA recommendations on things because there are a lot of interested parties in this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA guidance, pre-EUA submission, response times
REVIEW FLAG: False

QA Block 17-5
CLARIFIED QUESTION: What happens if an antigen test submission is deemed incomplete during the initial review?
CLARIFIED ANSWER: If an antigen test submission is incomplete during review, the FDA will inform the submitter within a few days.
VERBATIM QUESTION: What happens if an antigen test submission is deemed incomplete during the initial review?
VERBATIM ANSWER: Once an antigen test is received, it's quickly reviewed for completeness. If it's not complete, we'll get back to you in a few days letting you know it's not complete.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test review process, Submission completeness review
REVIEW FLAG: False

QA Block 17-6
CLARIFIED QUESTION: How does the FDA prioritize different submissions, such as those from the ITAP and RADx programs?
CLARIFIED ANSWER: Once submissions are accepted for review, antigen tests are the highest priority within the FDA, with monitoring to ensure timely processing. The FDA receives many submissions, including through ITAP and RADx, adding to the high workload.
VERBATIM QUESTION: How does the FDA prioritize different submissions, such as those from the ITAP and RADx programs?
VERBATIM ANSWER: But once it's accepted for review, this is the highest priority area within the FDA. And I would personally routinely monitor turnaround times on this and speak to the antigen team to make sure that we move these things along quickly. But unfortunately, we can't promise any defined turnaround time. We are seeing a lot of submissions through the ITAP program and through the RADx program. And so, in addition to other submissions, we are continuing to have a high volume of antigen test submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission prioritization, ITAP program, RADx program
REVIEW FLAG: False

QA Block 17-7
CLARIFIED QUESTION: What measures are in place to manage the high volume of antigen test submissions effectively?
CLARIFIED ANSWER: Antigen test submissions are reviewed for completeness and flagged if incomplete within a few days. Accepted submissions receive the FDA's highest priority, with turnaround times monitored for efficiency. High volume submissions are also managed through ITAP and RADx programs.
VERBATIM QUESTION: What measures are in place to manage the high volume of antigen test submissions effectively?
VERBATIM ANSWER: Once an antigen test is received, it's quickly reviewed for completeness. If it's not complete, we'll get back to you in a few days letting you know it's not complete. But once it's accepted for review, this is the highest priority area within the FDA. And I would personally routinely monitor turnaround times on this and speak to the antigen team to make sure that we move these things along quickly. But unfortunately, we can't promise any defined turnaround time. We are seeing a lot of submissions through the ITAP program and through the RADx program. And so, in addition to other submissions, we are continuing to have a high volume of antigen test submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test reviews, submission prioritization, programs to handle volume
REVIEW FLAG: False


#### 18. Transition from Qualified to Unqualified CDC Reagents

QA Block 18-1
CLARIFIED QUESTION: What is meant by 'qualified' CDC primers and probes?
CLARIFIED ANSWER: 'Qualified' CDC primers and probes refer to reagent lots that were reviewed and approved by CDC to ensure suitability for their authorized assays, but the CDC has stopped qualifying these lots for single analyte tests.
VERBATIM QUESTION: What is meant by 'qualified' CDC primers and probes?
VERBATIM ANSWER: Yeah, so the CDC announced that they were no longer supporting their SARS-CoV-2 single analyte test. They announced this last summer. While they were supporting the test, they were qualifying lots of reagents that were sold by IDT, which is a reagent manufacturer. And so, private labs could purchase those qualified lots of reagents from IDT and been able to offer or to perform the CDC assay as authorized. Since CDC is no longer supporting that assay, they are no longer qualifying lots that are distributed by IDT. But IDT is continuing to distribute unqualified lots or RUO lots. And so in that situation, a laboratory would have to qualify those lots themselves.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC qualified primers, reagents approval process
REVIEW FLAG: False

QA Block 18-2
CLARIFIED QUESTION: Does the lack of CDC support for the single analyte test mean private laboratories cannot access qualified primers and probes?
CLARIFIED ANSWER: The CDC stopped supporting the SARS-CoV-2 single analyte test, thus ceasing to qualify lots of reagents sold by IDT. While IDT still sells unqualified lots, private laboratories must now qualify these themselves.
VERBATIM QUESTION: Does the lack of CDC support for the single analyte test mean private laboratories cannot access qualified primers and probes?
VERBATIM ANSWER: Yeah, so the CDC announced that they were no longer supporting their SARS-CoV-2 single analyte test. They announced this last summer. While they were supporting the test, they were qualifying lots of reagents that were sold by IDT, which is a reagent manufacturer. And so, private labs could purchase those qualified lots of reagents from IDT and been able to offer or to perform the CDC assay as authorized. Since CDC is no longer supporting that assay, they are no longer qualifying lots that are distributed by IDT. But IDT is continuing to distribute unqualified lots or RUO lots. And so in that situation, a laboratory would have to qualify those lots themselves.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC SARS-CoV-2 single analyte test, qualified primers and probes, private laboratories
REVIEW FLAG: False

QA Block 18-3
CLARIFIED QUESTION: If a laboratory has qualified primer probes, can their assays still be used as a comparator for antigen tests?
CLARIFIED ANSWER: Yes, assays using qualified primer probes from CDC-approved lots can still be used as comparators for antigen tests, provided the lots were qualified before September 2021 and verified with the supplier. However, CDC advises labs to transition away from them.
VERBATIM QUESTION: If a laboratory has qualified primer probes, can their assays still be used as a comparator for antigen tests?
VERBATIM ANSWER: Yes, if you have-- if you have purchased lots that were qualified by either of the two sources while the CDC was still qualifying them. Those were all sold, well, I think the last sales were on and around or before September of 2021. Just check with whoever you purchase them from, IDT or Biosearch, and determine if your lots were qualified by the CDC or not. The CDC EUA remains in force, and those tests can continue to be used, although the CDC has recommended that labs move away from that because those qualified lots are going on-- those qualified tests are going away.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: qualified primer probes, antigen test comparator, CDC qualification
REVIEW FLAG: False

QA Block 18-4
CLARIFIED QUESTION: What should laboratories do to qualify unqualified lots of reagents distributed by IDT or Biosearch?
CLARIFIED ANSWER: Laboratories must qualify unqualified reagent lots distributed by IDT or Biosearch themselves, as the CDC no longer qualifies those lots.
VERBATIM QUESTION: What should laboratories do to qualify unqualified lots of reagents distributed by IDT or Biosearch?
VERBATIM ANSWER: Since CDC is no longer supporting that assay, they are no longer qualifying lots that are distributed by IDT. But IDT is continuing to distribute unqualified lots or RUO lots. And so in that situation, a laboratory would have to qualify those lots themselves. And I would just add that in the early days, Biosearch also had lots that were qualified by the CDC, but they have also ceased distributing those qualified lots.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Reagent qualification, CDC assay support
REVIEW FLAG: False

QA Block 18-5
CLARIFIED QUESTION: Are CDC-qualified lots still being distributed for any SARS-CoV-2 assays?
CLARIFIED ANSWER: Qualified lots for the SARS-CoV-2 single analyte test are no longer being distributed as the CDC stopped supporting this test. Qualified lots for the multi-analyte test are still being distributed but only to public health labs.
VERBATIM QUESTION: Are CDC-qualified lots still being distributed for any SARS-CoV-2 assays?
VERBATIM ANSWER: The CDC announced that they were no longer supporting their SARS-CoV-2 single analyte test. They announced this last summer. While they were supporting the test, they were qualifying lots of reagents that were sold by IDT, which is a reagent manufacturer. And so, private labs could purchase those qualified lots of reagents from IDT and been able to offer or to perform the CDC assay as authorized. Since CDC is no longer supporting that assay, they are no longer qualifying lots that are distributed by IDT. But IDT is continuing to distribute unqualified lots or RUO lots. And so in that situation, a laboratory would have to qualify those lots themselves. And I would just add that in the early days, Biosearch also had lots that were qualified by the CDC, but they have also ceased distributing those qualified lots. And just to add that the CDC is still supporting the multi-analyte test so there are still qualified lots for that test being sold. But I don't believe they're being sold independently. I could be wrong. I don't think the CDC was ever qualifying those tests to be made by other manufacturers, those multi-analyte meaning flu and SARS-CoV-2 are only being distributed to public health labs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC-qualified lots, SARS-CoV-2 diagnostics, Multi-analyte assay distribution
REVIEW FLAG: False

QA Block 18-6
CLARIFIED QUESTION: How can laboratories verify if their purchased lots were CDC-qualified before September 2021?
CLARIFIED ANSWER: To verify if their purchased lots were CDC-qualified before September 2021, laboratories should contact the supplier (either IDT or Biosearch) to confirm their qualification status while the CDC was still qualifying them.
VERBATIM QUESTION: How can laboratories verify if their purchased lots were CDC-qualified before September 2021?
VERBATIM ANSWER: Yes, if you have-- if you have purchased lots that were qualified by either of the two sources while the CDC was still qualifying them. Those were all sold, well, I think the last sales were on and around or before September of 2021. Just check with whoever you purchase them from, IDT or Biosearch, and determine if your lots were qualified by the CDC or not. The CDC EUA remains in force, and those tests can continue to be used, although the CDC has recommended that labs move away from that because those qualified lots are going on-- those qualified tests are going away.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC-qualified lots, laboratory verification, EUA tests
REVIEW FLAG: False

QA Block 18-7
CLARIFIED QUESTION: Are the CDC multi-analyte tests only available to public health laboratories?
CLARIFIED ANSWER: CDC multi-analyte tests for flu and SARS-CoV-2 are only being distributed to public health laboratories, not sold independently or through other manufacturers.
VERBATIM QUESTION: Are the CDC multi-analyte tests only available to public health laboratories?
VERBATIM ANSWER: I don't believe they're being sold independently. I could be wrong. I don't think the CDC was ever qualifying those tests to be made by other manufacturers, those multi-analyte meaning flu and SARS-CoV-2 are only being distributed to public health labs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC multi-analyte tests, test distribution, public health labs
REVIEW FLAG: False

QA Block 18-8
CLARIFIED QUESTION: What are the implications for laboratories using CDC assays given that qualified lots are being phased out?
CLARIFIED ANSWER: The CDC stopped supporting their SARS-CoV-2 single analyte test and no longer qualifies lots of reagents for it. Labs already using qualified lots, which were last sold around September 2021, may continue to use them under the CDC EUA, but the CDC recommends transitioning away since qualified lots are no longer supported. For multi-analyte tests, qualified lots are still available but only for public health labs.
VERBATIM QUESTION: What are the implications for laboratories using CDC assays given that qualified lots are being phased out?
VERBATIM ANSWER: Yeah, so the CDC announced that they were no longer supporting their SARS-CoV-2 single analyte test. They announced this last summer. While they were supporting the test, they were qualifying lots of reagents that were sold by IDT, which is a reagent manufacturer. And so, private labs could purchase those qualified lots of reagents from IDT and been able to offer or to perform the CDC assay as authorized. Since CDC is no longer supporting that assay, they are no longer qualifying lots that are distributed by IDT. But IDT is continuing to distribute unqualified lots or RUO lots. And so in that situation, a laboratory would have to qualify those lots themselves. And I would just add that in the early days, Biosearch also had lots that were qualified by the CDC, but they have also ceased distributing those qualified lots. Yes, if you have-- if you have purchased lots that were qualified by either of the two sources while the CDC was still qualifying them. Those were all sold, well, I think the last sales were on and around or before September of 2021. Just check with whoever you purchase them from, IDT or Biosearch, and determine if your lots were qualified by the CDC or not. The CDC EUA remains in force, and those tests can continue to be used, although the CDC has recommended that labs move away from that because those qualified lots are going on-- those qualified tests are going away. And just to add that the CDC is still supporting the multi-analyte test so there are still qualified lots for that test being sold. But I don't believe they're being sold independently. I could be wrong. I don't think the CDC was ever qualifying those tests to be made by other manufacturers, those multi-analyte meaning flu and SARS-CoV-2 are only being distributed to public health labs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC assay support ending, Labs qualifying reagents, Multi-analyte tests
REVIEW FLAG: False


#### 19. CLIA Lab Responsibilities for EUA Test Validations

QA Block 19-1
CLARIFIED QUESTION: What is the responsibility of a CLIA certified lab in confirming that an EUA is still valid and not revoked for tests they have been using?
CLARIFIED ANSWER: EUAs are rarely revoked. If revoked "for cause," there will be an announcement and likely recall notification. Other revocations are typically due to manufacturer withdrawal and are posted on the FDA EUA website. Labs should check the website to ensure authorization remains valid; companies will notify customers of any active revocations.
VERBATIM QUESTION: What is the responsibility of a CLIA certified lab in confirming that an EUA is still valid and not revoked for tests they have been using?
VERBATIM ANSWER: Yeah, so the EUAs are not revoked often. If an EUA is revoked "for cause," quote unquote, because an issue is discovered, that would be-- there would be an announcement about that. And we would also likely ask the company to perform a recall, so to notify all of their customers. Other revocations are typically for when the manufacturer has decided that they no longer want to support their test. And so they ask us to revoke it. Those are all posted on our website. So if you look on our EUA website, as long as the test that you're using is there, there's nothing that you should be concerned about. And if anything is revoked that's in active distribution, generally an announcement will be sent by the company to their customers.
SPEAKER QUESTION: Najwa Lamnii
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA lab responsibilities, EUA validity checks, Revocation notifications
REVIEW FLAG: False

QA Block 19-3
CLARIFIED QUESTION: Do we need to ensure that a test remains authorized or check if its EUA has been revoked?
CLARIFIED ANSWER: EUAs are rarely revoked. If revoked due to an issue, there would be an announcement, and the manufacturer would likely notify customers. For manufacturer-requested revocations, these are posted on the EUA website. Labs can check the website to confirm a test remains authorized.
VERBATIM QUESTION: Do we need to ensure that a test remains authorized or check if its EUA has been revoked?
VERBATIM ANSWER: Yeah, so the EUAs are not revoked often. If an EUA is revoked "for cause," quote unquote, because an issue is discovered, that would be-- there would be an announcement about that. And we would also likely ask the company to perform a recall, so to notify all of their customers. Other revocations are typically for when the manufacturer has decided that they no longer want to support their test. And so they ask us to revoke it. Those are all posted on our website. So if you look on our EUA website, as long as the test that you're using is there, there's nothing that you should be concerned about. And if anything is revoked that's in active distribution, generally an announcement will be sent by the company to their customers.
SPEAKER QUESTION: Najwa Lamnii
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation, Lab responsibilities, FDA guidance
REVIEW FLAG: False

QA Block 19-4
CLARIFIED QUESTION: What specific policies under CLIA must be followed if using an EUA-authorized manufactured kit?
CLARIFIED ANSWER: FDA states they do not have specific recommendations for labs using EUA-authorized manufactured kits, but CLIA likely has relevant policies that labs must follow.
VERBATIM QUESTION: What specific policies under CLIA must be followed if using an EUA-authorized manufactured kit?
VERBATIM ANSWER: So if you're buying a manufactured kit that is either that is EUA authorized, the FDA does not have any recommendations on what the lab would do. But I believe CLIA has some policies that need to be followed for that.
SPEAKER QUESTION: Najwa Lamnii
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA policies, EUA-authorized kits, lab responsibilities
REVIEW FLAG: False

QA Block 19-5
CLARIFIED QUESTION: What steps should a lab take if using a test that is notified but not yet EUA authorized?
CLARIFIED ANSWER: The FDA referred to earlier remarks which clarified measures for labs using tests that are notified but not yet EUA-authorized.
VERBATIM QUESTION: What steps should a lab take if using a test that is notified but not yet EUA authorized?
VERBATIM ANSWER: Toby covered what labs might need to do if the test is notified and not yet in on the notification list, but not yet EUA authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: notified tests, EUA authorization, lab responsibilities
REVIEW FLAG: False

QA Block 19-7
CLARIFIED QUESTION: What procedures are followed if an EUA is revoked "for cause" due to an issue being discovered?
CLARIFIED ANSWER: If an EUA is revoked "for cause" due to an issue being discovered, the FDA makes an announcement and likely asks the company to perform a recall to notify their customers. Revocations for other reasons are also posted on the FDA's EUA website.
VERBATIM QUESTION: What procedures are followed if an EUA is revoked "for cause" due to an issue being discovered?
VERBATIM ANSWER: Yeah, so the EUAs are not revoked often. If an EUA is revoked "for cause," quote unquote, because an issue is discovered, that would be-- there would be an announcement about that. And we would also likely ask the company to perform a recall, so to notify all of their customers. Other revocations are typically for when the manufacturer has decided that they no longer want to support their test. And so they ask us to revoke it. Those are all posted on our website. So if you look on our EUA website, as long as the test that you're using is there, there's nothing that you should be concerned about. And if anything is revoked that's in active distribution, generally an announcement will be sent by the company to their customers.
SPEAKER QUESTION: Najwa Lamnii
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation process, Manufacturer recalls, FDA website for updates
REVIEW FLAG: False

QA Block 19-8
CLARIFIED QUESTION: If a test's EUA is revoked and it's in active distribution, what notification responsibilities do manufacturers have?
CLARIFIED ANSWER: If an EUA is revoked due to an issue, the FDA announces it and usually asks the manufacturer to recall and notify customers. For other revocations, such as when manufacturers no longer support a test, these are posted on the FDA's EUA website. Manufacturers generally send announcements for revoked tests in active distribution.
VERBATIM QUESTION: If a test's EUA is revoked and it's in active distribution, what notification responsibilities do manufacturers have?
VERBATIM ANSWER: Yeah, so the EUAs are not revoked often. If an EUA is revoked "for cause," quote unquote, because an issue is discovered, that would be-- there would be an announcement about that. And we would also likely ask the company to perform a recall, so to notify all of their customers. Other revocations are typically for when the manufacturer has decided that they no longer want to support their test. And so they ask us to revoke it. Those are all posted on our website. So if you look on our EUA website, as long as the test that you're using is there, there's nothing that you should be concerned about. And if anything is revoked that's in active distribution, generally an announcement will be sent by the company to their customers.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation, Manufacturer notifications, Active distribution recalls
REVIEW FLAG: False


#### 20. Clarifying LDT EUA Policy and Site Expansion Rules

QA Block 20-1
CLARIFIED QUESTION: Can we continue to offer an LDT test while the EUA request is under review, even if the FDA website lists the test as not authorized?
CLARIFIED ANSWER: Yes, the FDA allows you to continue offering the LDT while the EUA request is under review, unless you receive a notice explicitly stating a decline to review or issue.
VERBATIM QUESTION: Can we continue to offer an LDT test while the EUA request is under review, even if the FDA website lists the test as not authorized?
VERBATIM ANSWER: OK, then yes, under that policy, you can continue to offer the LDT unless and until we send you a notice saying that we've declined to review or declined to issue rather, and in which case, that letter would then spell out what we expect you to do.
SPEAKER QUESTION: Geetha Rao
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: LDT policy, EUA review process
REVIEW FLAG: False

QA Block 20-2
CLARIFIED QUESTION: Is it acceptable to create a second CLIA certified site for offering the same test, provided everything remains internal?
CLARIFIED ANSWER: FDA recommends submitting the question about creating a second CLIA-certified site for the test to the Templates email address to ensure full understanding and receive proper feedback.
VERBATIM QUESTION: Is it acceptable to create a second CLIA certified site for offering the same test, provided everything remains internal?
VERBATIM ANSWER: That would turn the test into probably not being an LDT. So I would submit that specific question into the Agency to our Templates email address so that we can make sure that we understand all the facts and can give you the right feedback on what to do in that situation.
SPEAKER QUESTION: Geetha Rao
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-certified site, LDT status, FDA feedback
REVIEW FLAG: False

QA Block 20-3
CLARIFIED QUESTION: What is the significance of the November 15, 2021, guidance for LDTs continuing under review?
CLARIFIED ANSWER: Under the November 15, 2021, guidance, an LDT can continue to be offered while under FDA review unless a notice of declined review or issuance is sent. Tests remain unauthorized until officially determined otherwise, as reflected on the notification list.
VERBATIM QUESTION: What is the significance of the November 15, 2021, guidance for LDTs continuing under review?
VERBATIM ANSWER: Then unless it's under the umbrella policy of November 15, 2021, it is still not authorized. So that notification list is still correct. And there, as Toby said, there's no issues with you continuing to use that test while the FDA reviews. If we have any issues, we will reach back out. We hope those are few and far behind-- few and uncommon. But we will reach out. And all the while, we'll try to work with you to get that test back on to stay on the market. All right?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: November 15, 2021 policy, LDT authorization status, FDA submission review
REVIEW FLAG: False

QA Block 20-4
CLARIFIED QUESTION: What specific issues might arise during FDA's review that would require the Agency to reach back out to LDT developers?
CLARIFIED ANSWER: The FDA may contact LDT developers if issues arise during the review process, but such instances are expected to be uncommon. The FDA will collaborate with developers to address any problems and aim to keep the test on the market.
VERBATIM QUESTION: What specific issues might arise during FDA's review that would require the Agency to reach back out to LDT developers?
VERBATIM ANSWER: Then unless it's under the umbrella policy of November 15, 2021, it is still not authorized. So that notification list is still correct. And there, as Toby said, there's no issues with you continuing to use that test while the FDA reviews. If we have any issues, we will reach back out. We hope those are few and far behind-- few and uncommon. But we will reach out. And all the while, we'll try to work with you to get that test back on to stay on the market.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT EUA review, FDA communication
REVIEW FLAG: False

QA Block 20-5
CLARIFIED QUESTION: When does a test offered at multiple CLIA-certified labs cease to qualify as an LDT?
CLARIFIED ANSWER: A test offered at multiple CLIA-certified labs likely would no longer qualify as an LDT. FDA recommends submitting the specific details for review through their Templates email address.
VERBATIM QUESTION: When does a test offered at multiple CLIA-certified labs cease to qualify as an LDT?
VERBATIM ANSWER: That would turn the test into probably not being an LDT. So I would submit that specific question into the Agency to our Templates email address so that we can make sure that we understand all the facts and can give you the right feedback on what to do in that situation.
SPEAKER QUESTION: Geetha Rao
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT criteria, Multiple CLIA-certified labs, FDA submission process
REVIEW FLAG: False

QA Block 20-6
CLARIFIED QUESTION: What details should be included when submitting questions about multiple CLIA sites to the Templates email address?
CLARIFIED ANSWER: Submit detailed facts about the multiple CLIA sites to the Templates email address so that FDA can provide accurate feedback.
VERBATIM QUESTION: What details should be included when submitting questions about multiple CLIA sites to the Templates email address?
VERBATIM ANSWER: That would turn the test into probably not being an LDT. So I would submit that specific question into the Agency to our Templates email address so that we can make sure that we understand all the facts and can give you the right feedback on what to do in that situation.
SPEAKER QUESTION: Geetha Rao
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA site submission, Templates email process, LDT status
REVIEW FLAG: False

QA Block 20-7
CLARIFIED QUESTION: Does the listing of an LDT as 'not authorized' on the FDA website imply immediate cessation of its use?
CLARIFIED ANSWER: The listing of an LDT as 'not authorized' on the FDA website does not require cessation of use while the FDA review is ongoing, as long as it complies with the November 15, 2021, policy.
VERBATIM QUESTION: Does the listing of an LDT as 'not authorized' on the FDA website imply immediate cessation of its use?
VERBATIM ANSWER: Then unless it's under the umbrella policy of November 15, 2021, it is still not authorized. So that notification list is still correct. And there, as Toby said, there's no issues with you continuing to use that test while the FDA reviews. If we have any issues, we will reach back out. We hope those are few and far behind-- few and uncommon. But we will reach out. And all the while, we'll try to work with you to get that test back on to stay on the market.
SPEAKER QUESTION: Geetha Rao
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT authorization status, FDA review policies
REVIEW FLAG: False


#### 21. Balancing Usability Studies for Paper and App Instructions

QA Block 21-1
CLARIFIED QUESTION: Is it the expectation that there should be 30 participants for both the paper-based instructions and 30 for the app in a usability study?
CLARIFIED ANSWER: The FDA does not expect duplication of 30 participants for both paper-based and app-based instructions but recommends emailing for clarification.
VERBATIM QUESTION: Is it the expectation that there should be 30 participants for both the paper-based instructions and 30 for the app in a usability study?
VERBATIM ANSWER: Yeah, unfortunately, I don't have an answer for you now. But I know we've addressed this in the past for other folks. And certainly, we're not going to duplicate 30 folks for both the paper and form based instructions. So I think if you can just email me that question. Or sorry, email the Templates inbox and have them CC me. I can get you that answer pretty quick. But that would be ask for Kris Roth to be brought in, and he'll get you a quick answer.
SPEAKER QUESTION: Karen S.
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability study participant numbers, paper-based and app instructions
REVIEW FLAG: False

QA Block 21-2
CLARIFIED QUESTION: Can a hybrid option be used with 30 paper-based participants and an additional 10 participants for the app in a usability study?
CLARIFIED ANSWER: FDA indicated that they do not duplicate 30 participants for both paper and app-based instructions. The person was advised to email the Templates inbox and copy Kris Roth for a detailed answer.
VERBATIM QUESTION: Can a hybrid option be used with 30 paper-based participants and an additional 10 participants for the app in a usability study?
VERBATIM ANSWER: Yeah, unfortunately, I don't have an answer for you now. But I know we've addressed this in the past for other folks. And certainly, we're not going to duplicate 30 folks for both the paper and form based instructions. So I think if you can just email me that question. Or sorry, email the Templates inbox and have them CC me. I can get you that answer pretty quick. But that would be ask for Kris Roth to be brought in, and he'll get you a quick answer.
SPEAKER QUESTION: Karen S.
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability study design, participant duplication, contact for follow-up
REVIEW FLAG: False

QA Block 21-3
CLARIFIED QUESTION: Should I email the Templates inbox to get clarification about the number of participants required for paper-based and app-based usability studies?
CLARIFIED ANSWER: FDA advises emailing the Templates inbox (CC Kris Roth) for clarification regarding participant numbers for paper-based and app-based usability studies.
VERBATIM QUESTION: Should I email the Templates inbox to get clarification about the number of participants required for paper-based and app-based usability studies?
VERBATIM ANSWER: Yeah, unfortunately, I don't have an answer for you now. But I know we've addressed this in the past for other folks. And certainly, we're not going to duplicate 30 folks for both the paper and form based instructions. So I think if you can just email me that question. Or sorry, email the Templates inbox and have them CC me. I can get you that answer pretty quick. But that would be ask for Kris Roth to be brought in, and he'll get you a quick answer.
SPEAKER QUESTION: Karen S.
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability study participant clarification, emailing Templates inbox
REVIEW FLAG: False

QA Block 21-4
CLARIFIED QUESTION: How does using an app for interpretation impact performance in a usability or clinical study?
CLARIFIED ANSWER: FDA wants to know how using an app for interpretation impacts usability and potentially clinical study performance, since it may differ from using instructions in other forms.
VERBATIM QUESTION: How does using an app for interpretation impact performance in a usability or clinical study?
VERBATIM ANSWER: One thing that I just want to add. I think that I heard you say that the app is not needed for interpretation, but can help. I think Tim mentioned that this would also feed into your clinical study a bit. And so that is one consideration that we do want to see how the performance may be impacted with that step. So we would want that. And again, if you send us in and copy Kris, we can make sure that we get you the right feedback there. But just wanted to point out that we would want to see how the different sets of instructions and especially with using an app for interpretation would impact performance or potentially impact performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: App impact on performance, Usability studies, Clinical studies
REVIEW FLAG: False

QA Block 21-5
CLARIFIED QUESTION: How does the app differ from the paper version in helping individuals perform the test?
CLARIFIED ANSWER: The FDA wants to evaluate how the app assists differently from the paper version in helping individuals perform the test.
VERBATIM QUESTION: How does the app differ from the paper version in helping individuals perform the test?
VERBATIM ANSWER: Right, right, so we would just want to know how the app differs-- in your email to Kris, how the app differs from the paper version in helping individuals do the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: App vs. paper usability, Test interpretation, FDA evaluation
REVIEW FLAG: False

QA Block 21-6
CLARIFIED QUESTION: What is the FDA's stance on requiring separate studies for paper-based and app-based usability instructions?
CLARIFIED ANSWER: The FDA focuses on the acceptability of paper-based instructions and does not require duplicative studies for both paper and app-based instructions, although how apps supplement instructions may still need evaluation.
VERBATIM QUESTION: What is the FDA's stance on requiring separate studies for paper-based and app-based usability instructions?
VERBATIM ANSWER: The FDA doesn't assume somebody gets a kit, that where the instructions need to be provided, that are provided always in paper, that everybody will have access to the internet and access to an electronic form. And so our primary focus is on the acceptability of the paper version. We're not opposed to extra training materials or the use of electronic instructions. As far as how to-- and I would hope that we wouldn't require you to do two studies or twice as much usability study, so I'm not sure if-- hopefully Kris is still on and/or Toby can respond about any more specificity to this.
SPEAKER QUESTION: Karen S.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability study requirements, paper vs. app usability, FDA testing expectations
REVIEW FLAG: False

QA Block 21-7
CLARIFIED QUESTION: Is the FDA's primary focus on the usability of paper instructions due to assumed internet inaccessibility?
CLARIFIED ANSWER: FDA focuses on the acceptability of paper instructions due to the assumption that not everyone will have internet access, though they are open to supplementary electronic instructions.
VERBATIM QUESTION: Is the FDA's primary focus on the usability of paper instructions due to assumed internet inaccessibility?
VERBATIM ANSWER: The FDA doesn't assume somebody gets a kit, that where the instructions need to be provided, that are provided always in paper, that everybody will have access to the internet and access to an electronic form. And so our primary focus is on the acceptability of the paper version. We're not opposed to extra training materials or the use of electronic instructions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability of paper instructions, Internet access assumptions, Electronic instructions
REVIEW FLAG: False

QA Block 21-8
CLARIFIED QUESTION: Does the FDA recommend including both paper-based and app-based instructions in a kit to accommodate varied user access?
CLARIFIED ANSWER: The FDA primarily focuses on the usability of paper instructions, as not all users may have internet access, but does not oppose including electronic instructions or additional training materials.
VERBATIM QUESTION: Does the FDA recommend including both paper-based and app-based instructions in a kit to accommodate varied user access?
VERBATIM ANSWER: The FDA doesn't assume somebody gets a kit, that where the instructions need to be provided, that are provided always in paper, that everybody will have access to the internet and access to an electronic form. And so our primary focus is on the acceptability of the paper version. We're not opposed to extra training materials or the use of electronic instructions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Instruction formats in kits, Paper vs. electronic usability, Accessibility
REVIEW FLAG: False

QA Block 21-9
CLARIFIED QUESTION: How should developers demonstrate the performance impact of using app-based instruction within usability or clinical studies?
CLARIFIED ANSWER: FDA expects developers to show how using app-based instructions compared to paper instructions impacts performance, as part of both usability and clinical studies.
VERBATIM QUESTION: How should developers demonstrate the performance impact of using app-based instruction within usability or clinical studies?
VERBATIM ANSWER: I think Tim mentioned that this would also feed into your clinical study a bit. And so that is one consideration that we do want to see how the performance may be impacted with that step. So we would want that. And again, if you send us in and copy Kris, we can make sure that we get you the right feedback there. But just wanted to point out that we would want to see how the different sets of instructions and especially with using an app for interpretation would impact performance or potentially impact performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: app-based instructions, performance impact, clinical and usability studies
REVIEW FLAG: False

QA Block 21-11
CLARIFIED QUESTION: Under what circumstances does the FDA consider app-based interpretation to be equivalent to independently reading and interpreting a test?
CLARIFIED ANSWER: The FDA considers app-based interpretation equivalent to independently reading and interpreting a test only if the app is actually reading the test and making independent interpretations.
VERBATIM QUESTION: Under what circumstances does the FDA consider app-based interpretation to be equivalent to independently reading and interpreting a test?
VERBATIM ANSWER: Yeah, we would want to see the differences between paper and the app. And if the app is actually reading the test and independently interpreting it, then that's an entirely different situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: App-based interpretation, Test reading standards
REVIEW FLAG: False

QA Block 21-12
CLARIFIED QUESTION: What performance differences between paper instructions and app-based instructions does the FDA expect developers to evaluate?
CLARIFIED ANSWER: FDA expects developers to evaluate how app-based instructions impact performance compared to paper instructions, particularly if the app assists in interpretation.
VERBATIM QUESTION: What performance differences between paper instructions and app-based instructions does the FDA expect developers to evaluate?
VERBATIM ANSWER: One thing that I just want to add. I think that I heard you say that the app is not needed for interpretation, but can help. I think Tim mentioned that this would also feed into your clinical study a bit. And so that is one consideration that we do want to see how the performance may be impacted with that step. So we would want that. And again, if you send us in and copy Kris, we can make sure that we get you the right feedback there. But just wanted to point out that we would want to see how the different sets of instructions and especially with using an app for interpretation would impact performance or potentially impact performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Performance evaluation for instructions, Paper vs app-based usability
REVIEW FLAG: False

### removed qa blocks
QA Block 1-2
CLARIFIED QUESTION: Under what circumstances does an EUA holder require FDA concurrence for changes to labeling or distributors?
CLARIFIED ANSWER: FDA generally requires EUA holders to refer to their letter of authorization for specifics, but concurrence is typically needed for updated labeling, including new brand names. Adding a new distributor without changing labeling usually only requires FDA acknowledgment.
VERBATIM QUESTION: Under what circumstances does an EUA holder require FDA concurrence for changes to labeling or distributors?
VERBATIM ANSWER: Generally, we recommend that all EUA holders refer to their conditions of authorization in their letter of authorization to determine what needs to be sent to FDA and in which cases they need concurrence from FDA prior to implementation. In general, the conditions of authorization typically state that an EUA holder must tell the FDA of any new distributors and must have concurrence from FDA prior to implementation of any updated labeling, including any new brand names. So, the concurrence is generally only if there is updated labeling. If you are adding a new distributor without changing any labeling, we will generally acknowledge receipt, but you do not need to wait for concurrence. And that is, again, dependent on what is in your letter of authorization, but that is the typical situation for most EUAs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA concurrence, Labeling updates, Distributor notification
REVIEW FLAG: False

QA Block 4-1
CLARIFIED QUESTION: Will FDA consider throat swabs for at-home COVID-19 diagnostic tests?
CLARIFIED ANSWER: The FDA is open to considering throat swabs for at-home tests if safety concerns are addressed, though they face challenges such as lower sensitivity compared to nasal swabs, safety risks during sample collection, and potential variability between variants. Current evidence suggests nasal swabs remain more effective.
VERBATIM QUESTION: Will FDA consider throat swabs for at-home COVID-19 diagnostic tests?
VERBATIM ANSWER: Thank you, Joe. Short answer is yes, but let me go into some detail. As stated in the previous Town Hall meeting, the CDC does recommend that throat swabs be collected only by trained health care providers. While the FDA is open to the sample type for rapid tests with data demonstrating that the safety concerns have been addressed, there has been some new evidence published. That's a UCSF paper preprint that is on the slide deck and can be referred to. I will briefly outline the key findings from that paper. They examined the use of an oral cheek swab and what they call a throat swab, which I believe is an oropharyngeal swab, for use with one of the EUA-authorized rapid antigen tests. And they compared it to nasal swab and did have a PCR comparator as well. They found that either the cheek swab or the oropharyngeal swab alone had sensitivities that were considerably below the nasal swab alone. And when they obtained a combo nasal and oropharyngeal swab, the slight sensitivity improvement was, in their opinion, did not benefit testing enough considering the risks of oropharyngeal swabs, both to health care workers who might be performing it and to the user. There is frequently gagging and even throwing up. This can potentially spread disease within the health care environment, and obviously, would also be a problem at home in obtaining an adequate sample. Also, omicron may be unique in its tissue where it replicates more readily versus the other viral variants. For example, the previously mentioned South African paper showed for delta that a nasal swab was better than saliva in their hand. So it would be a lot of work to go through and validate something that may not be the best thing for patients or for care. And then you have the next variant come along and it returns it to being the nasal swab being the best. So I think that pretty much covers our thoughts on throat swabbing, so thank you.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Use of throat swabs in diagnostics, Comparison of swab effectiveness, Variant impact on swab efficacy
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: How should labs using a modified version of the CDC assay handle the use of the RUO (Research Use Only) reagents from IDT for testing?
CLARIFIED ANSWER: Labs using RUO reagents from IDT should include qualification procedures for each lot of reagents. CDC's qualification procedures can be obtained through FDA's EUA mailbox. Labs may offer a modified CDC assay under the November 15 policy but should consider submitting a new EUA request.
VERBATIM QUESTION: How should labs using a modified version of the CDC assay handle the use of the RUO (Research Use Only) reagents from IDT for testing?
VERBATIM ANSWER: So CDC, as we've discussed here before, has stopped qualifying lots for IDT to sell. They have stopped supporting their SARS-CoV-2-only assay. But they have also provided recommendations for laboratories that are using that CDC-- the original SARS-CoV-2 CDC assay to transition to another FDA authorized COVID-19 test. Laboratories that intend to continue performing testing using the RUO reagents, the non-qualified lots of reagents from IDT, should include qualification procedures for qualifying each lot of reagents that they purchase. CDC has provided their qualification procedures to FDA, and we're able to provide those to laboratories that need them. Excuse me. If you do need them, you can email the EUA mailbox and ask for those. Generally, since the CDC test is an authorized test, they still hold an EUA. Even though it is not being distributed any longer, labs may offer a modified version of the test under the modification policy that's included in the November 15 guidance. And so we do recommend that laboratories should consider the policies discussed in that November 15 version of the guidance the policy for coronavirus disease 2019 tests to determine whether they need to submit a new EUA request to the FDA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: RUO reagents use for CDC assay, Qualification processes, EUA modification policy
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: Where can laboratories obtain CDC qualification procedures for RUO reagents?
CLARIFIED ANSWER: Laboratories can obtain CDC qualification procedures for RUO reagents by emailing the FDA's EUA mailbox.
VERBATIM QUESTION: Where can laboratories obtain CDC qualification procedures for RUO reagents?
VERBATIM ANSWER: CDC has provided their qualification procedures to FDA, and we're able to provide those to laboratories that need them. Excuse me. If you do need them, you can email the EUA mailbox and ask for those.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC qualification procedures, RUO reagents, EUA mailbox
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: If still using the original CDC SARS-CoV-2 assay, are modifications to it permitted under the November 15 EUA guidance?
CLARIFIED ANSWER: FDA confirms that modifications to the original CDC SARS-CoV-2 assay are permitted under the November 15 EUA guidance. Laboratories should follow the guidance to determine if a new EUA request is required.
VERBATIM QUESTION: If still using the original CDC SARS-CoV-2 assay, are modifications to it permitted under the November 15 EUA guidance?
VERBATIM ANSWER: Generally, since the CDC test is an authorized test, they still hold an EUA. Even though it is not being distributed any longer, labs may offer a modified version of the test under the modification policy that's included in the November 15 guidance. And so we do recommend that laboratories should consider the policies discussed in that November 15 version of the guidance the policy for coronavirus disease 2019 tests to determine whether they need to submit a new EUA request to the FDA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CDC SARS-CoV-2 test modifications, November 15 EUA guidance
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Do we need to sequence every patient sample to confirm the omicron strain?
CLARIFIED ANSWER: The FDA generally wants sequence confirmation for omicron strain identification. If a clinical study has not been done yet, samples should be sequenced. Any study done currently will likely involve omicron, but sequencing confirms this. Those with existing submissions should coordinate with their lead reviewer to address required sample numbers.
VERBATIM QUESTION: Do we need to sequence every patient sample to confirm the omicron strain?
VERBATIM ANSWER: Eventually we'll want-- Yeah, eventually we want sequence confirmation, but it depends on the situation. So if you've not done your clinical study yet, yes, go ahead and sequence your clinical study samples. Omicron, last time I looked, was about 99% or greater in the US. So any study that's done right now is going to most likely be omicron, and the sequencing will confirm it. Just make sure the sequencing method has been validated in some way. If somebody is already in with a submission and we're now asking for omicron information, they should work that out with their lead reviewer about the number of samples we want to see because they may have already completed a study with delta and the other information we need about those samples prior to making an authorization decision.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sequencing for omicron, Clinical study requirements, FDA diagnostic guidance
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: How should developers validate the sequencing methods used to confirm omicron strains?
CLARIFIED ANSWER: FDA states that sequencing is required to confirm omicron in clinical study samples unless the study is complete. The sequencing method must be validated, and developers should consult their lead reviewer regarding required omicron data.
VERBATIM QUESTION: How should developers validate the sequencing methods used to confirm omicron strains?
VERBATIM ANSWER: Eventually we'll want-- Yeah, eventually we want sequence confirmation, but it depends on the situation. So if you've not done your clinical study yet, yes, go ahead and sequence your clinical study samples. Omicron, last time I looked, was about 99% or greater in the US. So any study that's done right now is going to most likely be omicron, and the sequencing will confirm it. Just make sure the sequencing method has been validated in some way. If somebody is already in with a submission and we're now asking for omicron information, they should work that out with their lead reviewer about the number of samples we want to see because they may have already completed a study with delta and the other information we need about those samples prior to making an authorization decision.
SPEAKER QUESTION: MHK
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sequencing method validation, omicron confirmation, clinical study submissions
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Are tests that do not meet FDA's volume criteria still permitted to be offered as LDTs?
CLARIFIED ANSWER: Tests that do not meet FDA's volume criteria cannot be offered as LDTs without EUA authorization.
VERBATIM QUESTION: Are tests that do not meet FDA's volume criteria still permitted to be offered as LDTs?
VERBATIM ANSWER: We will not review and, no, you cannot offer, as Toby said, without in an EUA authorization.
SPEAKER QUESTION: Rahul Sharma
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: volume criteria, LDT policy, EUA authorization
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Are specimen leftovers not suitable for asymptomatic studies but fine for symptomatic studies?
CLARIFIED ANSWER: Specimen leftovers are fine for symptomatic studies but must follow specific guidelines, such as testing individuals who have been symptomatic for no more than 14 days.
VERBATIM QUESTION: Are specimen leftovers not suitable for asymptomatic studies but fine for symptomatic studies?
VERBATIM ANSWER: Well, symptomatic's very straightforward. You test symptomatics. You probably want to limit how many days they've been symptomatic, and you don't want to probably go beyond 14 days. And you can look at other molecular authorizations.
SPEAKER QUESTION: Vitali Karaliou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: specimen leftovers, symptomatic testing, asymptomatic study limitations
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: What should be included in a shipping stability plan submitted as part of an EUA?
CLARIFIED ANSWER: FDA recommends submitting at least a shipping stability plan for review as part of your EUA.
VERBATIM QUESTION: What should be included in a shipping stability plan submitted as part of an EUA?
VERBATIM ANSWER: No, I think at least we'd want a plan and so we can discuss that plan in the context of your EUA.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: shipping stability plan, EUA submission requirements
REVIEW FLAG: False

QA Block 17-1
CLARIFIED QUESTION: What are the review times for pre-EUAs and EUAs for antigen tests currently?
CLARIFIED ANSWER: Antigen tests are reviewed for completeness upon receipt, with follow-up in a few days if incomplete. Accepted submissions receive high priority, but no defined turnaround time is guaranteed.
VERBATIM QUESTION: What are the review times for pre-EUAs and EUAs for antigen tests currently?
VERBATIM ANSWER: Once an antigen test is received, it's quickly reviewed for completeness. If it's not complete, we'll get back to you in a few days letting you know it's not complete. But once it's accepted for review, this is the highest priority area within the FDA. And I would personally routinely monitor turnaround times on this and speak to the antigen team to make sure that we move these things along quickly. But unfortunately, we can't promise any defined turnaround time.
SPEAKER QUESTION: Ela Heussen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA and EUA review times, antigen test priority, submission volume
REVIEW FLAG: False

QA Block 19-2
CLARIFIED QUESTION: Are there specific requirements for a CLIA lab to confirm EUA validity for tests they've already been using?
CLARIFIED ANSWER: FDA clarified that EUAs are rarely revoked, and when an EUA is revoked, announcements are made, and customers are usually notified by the manufacturer. Labs should verify the EUA status on the FDA EUA website.
VERBATIM QUESTION: Are there specific requirements for a CLIA lab to confirm EUA validity for tests they've already been using?
VERBATIM ANSWER: Yeah, so the EUAs are not revoked often. If an EUA is revoked "for cause," quote unquote, because an issue is discovered, that would be-- there would be an announcement about that. And we would also likely ask the company to perform a recall, so to notify all of their customers. Other revocations are typically for when the manufacturer has decided that they no longer want to support their test. And so they ask us to revoke it. Those are all posted on our website. So if you look on our EUA website, as long as the test that you're using is there, there's nothing that you should be concerned about. And if anything is revoked that's in active distribution, generally an announcement will be sent by the company to their customers.
SPEAKER QUESTION: Najwa Lamnii
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation process, Lab responsibilities, FDA website for EUA status
REVIEW FLAG: False

QA Block 19-6
CLARIFIED QUESTION: How are customers notified when an EUA is revoked due to a manufacturer's decision to no longer support the test?
CLARIFIED ANSWER: If a manufacturer decides to no longer support their test, they ask FDA to revoke the EUA. The revocation is posted on the EUA website, and manufacturers typically notify customers if the test is in active distribution.
VERBATIM QUESTION: How are customers notified when an EUA is revoked due to a manufacturer's decision to no longer support the test?
VERBATIM ANSWER: Other revocations are typically for when the manufacturer has decided that they no longer want to support their test. And so they ask us to revoke it. Those are all posted on our website. So if you look on our EUA website, as long as the test that you're using is there, there's nothing that you should be concerned about. And if anything is revoked that's in active distribution, generally an announcement will be sent by the company to their customers.
SPEAKER QUESTION: Najwa Lamnii
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation notifications, Manufacturer responsibilities, FDA's EUA website
REVIEW FLAG: False

QA Block 21-10
CLARIFIED QUESTION: What specific information should be included in an email to the Templates inbox to get clarification on usability study participant requirements?
CLARIFIED ANSWER: Email the Templates inbox and CC Kris Roth. Include your question about usability study participant requirements, and a quick response will be provided.
VERBATIM QUESTION: What specific information should be included in an email to the Templates inbox to get clarification on usability study participant requirements?
VERBATIM ANSWER: Yeah, unfortunately, I don't have an answer for you now. But I know we've addressed this in the past for other folks. And certainly, we're not going to duplicate 30 folks for both the paper and form based instructions. So I think if you can just email me that question. Or sorry, email the Templates inbox and have them CC me. I can get you that answer pretty quick. But that would be ask for Kris Roth to be brought in, and he'll get you a quick answer.
SPEAKER QUESTION: Karen S.
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Usability study participant requirements, Templates inbox, FDA clarification
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-05 05:40:38 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 21
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What should EUA holders review in their letter of authorization with regard to distributors and changes to labeling?
QI 1-2: Under what circumstances does an EUA holder require FDA concurrence for changes to labeling or distributors?
QI 1-3: What is the process for developers to get feedback on submitting a 510k for molecular SARS-CoV-2 tests?
QI 1-4: Do developers who have already made presubmissions for 510k need to take additional action to receive feedback?
QI 1-5: Why was the IVD EUA Molecular and Antigen webpage updated to include whether assays are single or multiple target tests?
QI 1-6: What steps should a developer take if their COVID-19 tests are shipped or stored in freezing temperatures?
QI 1-7: How can developers submit comments for clarification on the draft guidance titled 'The Transition Plan for Medical Devices Issued EUAs During the COVID-19 Public Health Emergency'?
QI 1-8: What details should be included in an email to the EUA Templates mailbox to receive feedback on managing current test development plans or transitions under the draft guidance?

#### Section 2 of 21
##### Explicit Questions Extraction
QE 2-1: What is required for a telehealth provider for home rapid tests?

##### Implicit Questions Extraction
QI 2-1: What performance data is needed to validate a test with telehealth proctoring?
QI 2-2: How should a developer demonstrate the accuracy of at-home tests under telehealth supervision in their EUA submission?
QI 2-3: Does the FDA specifically review the ability of telehealth proctors to guide users and interpret results?

#### Section 3 of 21
##### Explicit Questions Extraction
QE 3-1: How should test developers address the omicron variant in clinical studies for new antigen tests?

##### Implicit Questions Extraction
QI 3-1: What clinical data should be included in new EUA requests to address the omicron variant?
QI 3-2: What is the FDA's policy for evaluating the impact of viral mutations on COVID-19 tests?
QI 3-3: How does the FDA evaluate a test developer's plan for ongoing monitoring of new and emerging variants?
QI 3-4: What considerations should developers keep in mind regarding the impact of viral mutations, such as those in the omicron variant?
QI 3-5: What expectations should developers discuss with their FDA reviewer regarding test performance across known and emerging variants?

#### Section 4 of 21
##### Explicit Questions Extraction
QE 4-1: Will FDA consider throat swabs for at-home COVID-19 diagnostic tests?

##### Implicit Questions Extraction
QI 4-1: What does the FDA require to demonstrate the safety of throat swabs for at-home COVID-19 diagnostics?
QI 4-2: How does the sensitivity of oropharyngeal swabs compare to nasal swabs when used for rapid antigen tests?
QI 4-3: What are the safety risks associated with using oropharyngeal swabs for diagnostic purposes?
QI 4-4: Does the FDA consider the variability of virus behavior across different variants when assessing new sample types?
QI 4-5: What are the additional validation requirements for introducing combined nasal and oropharyngeal swabs for testing?
QI 4-6: How might the risks of gagging or vomiting during oropharyngeal sample collection affect at-home diagnostic test approval?

#### Section 5 of 21
##### Explicit Questions Extraction
QE 5-1: Does the test manufacturer have a duty to confirm a laboratory's CLIA registration status and type prior to shipment and maintain a record of this review, or does the responsibility fall with the laboratory to only use the test if qualified to do so?
QE 5-2: Is it acceptable to use the candidate test to screen negative clinical matrix used for analytical validation instead of using an authorized or cleared asset?
QE 5-3: How should labs using a modified version of the CDC assay handle the use of the RUO (Research Use Only) reagents from IDT for testing?

##### Implicit Questions Extraction
QI 5-1: What records of authorized laboratories and distributed test quantities should an EUA holder maintain as part of inventory control?
QI 5-2: Should EUA holders confirm they are distributing COVID-19 tests only to laboratories with appropriate qualifications?
QI 5-3: What qualification procedures should labs follow when using RUO reagents from non-qualified lots for a modified version of the CDC assay?
QI 5-4: Where can laboratories obtain CDC qualification procedures for RUO reagents?
QI 5-5: If still using the original CDC SARS-CoV-2 assay, are modifications to it permitted under the November 15 EUA guidance?
QI 5-6: Do laboratories need to submit a new EUA request if they modify the original CDC SARS-CoV-2 assay according to the November 15 guidance?

#### Section 6 of 21
##### Explicit Questions Extraction
QE 6-1: For an over-the-counter antigen all-comers clinical study, is it acceptable to exclude individuals for symptom onset greater than a certain number of days to exclude individuals with lingering symptoms?

##### Implicit Questions Extraction
QI 6-1: What information should be recorded for symptomatic individuals in an all-comers study?
QI 6-2: Should known exposures be recorded during data collection in an all-comers study?
QI 6-3: How should samples outside of the intended-use date range be treated in the primary determination of test agreement?
QI 6-4: What type of performance data is required to support an intended use for symptomatic individuals within a specific timeframe?

#### Section 7 of 21
##### Explicit Questions Extraction
QE 7-1: Is FDA considering changing the recommendation for 80% PPA with a 70% lower bound of the 95% confidence interval for rapid antigen tests to address the challenge in detecting the omicron variant?

##### Implicit Questions Extraction
QI 7-1: What is FDA's rationale for maintaining the current performance recommendations for antigen tests?
QI 7-2: How does the FDA recommend developers address the potential reduced sensitivity of rapid antigen tests to new variants such as omicron?
QI 7-3: Where can test developers find updates on the impact of SARS-CoV-2 variants on diagnostic test performance?
QI 7-4: Why do antigen tests carry a presumptive negative claim compared to molecular tests?
QI 7-5: How frequently is the FDA's SARS-CoV-2 viral mutations impact website updated?

#### Section 8 of 21
##### Explicit Questions Extraction
QE 8-1: Is FDA still considering emergency use authorizations for multi-analyte over-the-counter tests?

##### Implicit Questions Extraction

#### Section 9 of 21
##### Explicit Questions Extraction
QE 9-1: Is there a cutoff for the CT values for the data to present?
QE 9-2: Do the patient samples need to be sequenced to confirm the omicron strain, or how would you verify that the strain is present?
QE 9-3: How do we show that we have omicron data?
QE 9-4: Do we need to sequence every patient sample to confirm the omicron strain?

##### Implicit Questions Extraction
QI 9-1: What specific data is required to define low positives for an antigen SARS-CoV-2 test?
QI 9-2: Where can developers find detailed guidelines for submitting CT value data for antigen tests?
QI 9-3: What criteria must the comparator molecular test meet to be considered an acceptable high sensitivity test?
QI 9-4: How should developers validate the sequencing methods used to confirm omicron strains?
QI 9-5: What steps should be taken if a clinical study has already been completed with a different strain (e.g., delta) but additional omicron data is now required?

#### Section 10 of 21
##### Explicit Questions Extraction
QE 10-1: If we just start a clinical trial, do we need to confirm any sequence for omicron?
QE 10-2: For all positive samples in a clinical study, do you need sequencing confirmation?

##### Implicit Questions Extraction
QI 10-1: Why is sequencing analysis necessary for clinical trials even if omicron is the dominant variant?
QI 10-2: Under what circumstances might delta variants still be present during a clinical trial in the United States?
QI 10-3: What steps should be taken if a clinical trial encounters a higher proportion of delta cases than expected?

#### Section 11 of 21
##### Explicit Questions Extraction
QE 11-1: Do we have to submit for EUA or can we proceed as an LDT when starting a small RT-PCR based lab?
QE 11-2: Even if the test is conducted only to scale up testing and involves only 100 samples a day, does authorization still apply?
QE 11-3: Are tests that do not meet FDA's volume criteria still permitted to be offered as LDTs?
QE 11-4: Can new lab setups offer low volume testing without EUA authorization?

##### Implicit Questions Extraction
QI 11-1: What are the requirements for tests validated before November 15, 2021, in terms of volume metrics?
QI 11-2: Can low volume testing be performed with an FDA-authorized manufactured kit if not using an LDT?
QI 11-3: Does the FDA require a fully authorized EUA prior to any new testing, including LDTs?
QI 11-4: What is the volume minimum requirement that new tests must meet to substantially increase testing in the U.S.?
QI 11-5: Does the guidance apply to both manufactured kits and LDTs for new submissions?

#### Section 12 of 21
##### Explicit Questions Extraction
QE 12-1: Would data based on leftover specimens be potentially transferable into 510k?
QE 12-2: Do you have any comments on the inclusion of asymptomatic patient populations into this kind of study?
QE 12-3: Are specimen leftovers not suitable for asymptomatic studies but fine for symptomatic studies?

##### Implicit Questions Extraction
QI 12-1: What data or documentation would be required to demonstrate the validity of asymptomatic testing for EUAs?
QI 12-2: How does the FDA define proper collection methods when using leftover samples for testing?
QI 12-3: What are the acceptable limitations for including symptomatic individuals in clinical studies?
QI 12-4: Does the specific method of collecting leftover specimens impact their suitability for studies on asymptomatic testing?
QI 12-5: Are there templates or guidance documents detailing options for designing asymptomatic testing studies?

#### Section 13 of 21
##### Explicit Questions Extraction
QE 13-1: Is in silico analysis sufficient for a nucleocapsid test for the omicron variant, or is it necessary to include samples from omicron patients as well?

##### Implicit Questions Extraction
QI 13-1: Are omicron-specific clinical sample tests required for sequencing assays?
QI 13-2: What are the FDA's actions if concerns arise regarding variants or mutations during in silico analysis for molecular tests?
QI 13-3: Is FDA review required for molecular tests that do not rely on omicron patient samples?

#### Section 14 of 21
##### Explicit Questions Extraction
QE 14-1: Does the FDA have specific guidance or recommendations on which distribution simulation standards should be followed for a shipping stability study for molecular diagnostic tests?
QE 14-2: Is it necessary to include shipping stability data in a full EUA submission, or could it be provided during or after the process?

##### Implicit Questions Extraction
QI 14-1: Can developers propose an alternative ASTM shipping stability standard to the FDA if they believe it is more appropriate?
QI 14-2: What should be included in a shipping stability plan submitted as part of an EUA?
QI 14-3: In what circumstances could a discussion with the FDA team about incomplete shipping stability data influence the review process?
QI 14-4: Does the requirement to use dry ice for shipping serve as mitigation for temperature variations during transport?

#### Section 15 of 21
##### Explicit Questions Extraction
QE 15-1: With the recent change in the guidance, do new high complexity CLIA labs performing validation to run our kit make it be considered an LDT under FDA regulation, thus requiring them to submit and await approval of their EUA to run that test?
QE 15-2: Can it continue as before the change?

##### Implicit Questions Extraction
QI 15-1: What additional validation do high complexity CLIA labs need to perform for tests that are not yet FDA authorized?
QI 15-2: Under the November 15 guidance, can developers with an actively under-review EUA submission continue distributing their test kits?
QI 15-3: Can high complexity CLIA labs use test kits under the notification policy without submitting documentation to the FDA?
QI 15-4: Where can developers find written documentation or FAQs related to notification policies and test kit distribution?

#### Section 16 of 21
##### Explicit Questions Extraction
QE 16-1: Is the labeling issue with ACON tests legally resolved?
QE 16-2: Can the ACON test be purchased in the market right now?

##### Implicit Questions Extraction
QI 16-1: What precautions should be taken to avoid purchasing COVID-19 tests that are not EUA authorized?
QI 16-2: Are there certain identifiers or methods to verify that a COVID-19 test is indeed EUA authorized?
QI 16-3: Why should users in the United States avoid tests with CE marking that have not been reviewed by the FDA?
QI 16-4: Is contacting the manufacturer the recommended procedure for verifying authenticity of COVID-19 tests?

#### Section 17 of 21
##### Explicit Questions Extraction
QE 17-1: What are the review times for pre-EUAs and EUAs for antigen tests currently?
QE 17-2: When should one expect to hear back regarding pre-EUAs and EUAs for antigen tests?

##### Implicit Questions Extraction
QI 17-1: What types of questions should be restricted to pre-EUAs rather than using the standard templates?
QI 17-2: Are there specific recommendations for following the FDA guidance to ensure faster responses?
QI 17-3: What happens if an antigen test submission is deemed incomplete during the initial review?
QI 17-4: How does the FDA prioritize different submissions, such as those from the ITAP and RADx programs?
QI 17-5: What measures are in place to manage the high volume of antigen test submissions effectively?

#### Section 18 of 21
##### Explicit Questions Extraction
QE 18-1: What is meant by 'qualified' CDC primers and probes?
QE 18-2: Does the lack of CDC support for the single analyte test mean private laboratories cannot access qualified primers and probes?
QE 18-3: If a laboratory has qualified primer probes, can their assays still be used as a comparator for antigen tests?

##### Implicit Questions Extraction
QI 18-1: What should laboratories do to qualify unqualified lots of reagents distributed by IDT or Biosearch?
QI 18-2: Are CDC-qualified lots still being distributed for any SARS-CoV-2 assays?
QI 18-3: How can laboratories verify if their purchased lots were CDC-qualified before September 2021?
QI 18-4: Are the CDC multi-analyte tests only available to public health laboratories?
QI 18-5: What are the implications for laboratories using CDC assays given that qualified lots are being phased out?

#### Section 19 of 21
##### Explicit Questions Extraction
QE 19-1: What is the responsibility of a CLIA certified lab in confirming that an EUA is still valid and not revoked for tests they have been using?
QE 19-2: Are there specific requirements for a CLIA lab to confirm EUA validity for tests they've already been using?
QE 19-3: Do we need to ensure that a test remains authorized or check if its EUA has been revoked?

##### Implicit Questions Extraction
QI 19-1: What specific policies under CLIA must be followed if using an EUA-authorized manufactured kit?
QI 19-2: What steps should a lab take if using a test that is notified but not yet EUA authorized?
QI 19-3: How are customers notified when an EUA is revoked due to a manufacturer's decision to no longer support the test?
QI 19-4: What procedures are followed if an EUA is revoked "for cause" due to an issue being discovered?
QI 19-5: If a test's EUA is revoked and it's in active distribution, what notification responsibilities do manufacturers have?

#### Section 20 of 21
##### Explicit Questions Extraction
QE 20-1: Can we continue to offer an LDT test while the EUA request is under review, even if the FDA website lists the test as not authorized?
QE 20-2: Is it acceptable to create a second CLIA certified site for offering the same test, provided everything remains internal?

##### Implicit Questions Extraction
QI 20-1: What is the significance of the November 15, 2021, guidance for LDTs continuing under review?
QI 20-2: What specific issues might arise during FDA's review that would require the Agency to reach back out to LDT developers?
QI 20-3: When does a test offered at multiple CLIA-certified labs cease to qualify as an LDT?
QI 20-4: What details should be included when submitting questions about multiple CLIA sites to the Templates email address?
QI 20-5: Does the listing of an LDT as 'not authorized' on the FDA website imply immediate cessation of its use?

#### Section 21 of 21
##### Explicit Questions Extraction
QE 21-1: Is it the expectation that there should be 30 participants for both the paper-based instructions and 30 for the app in a usability study?
QE 21-2: Can a hybrid option be used with 30 paper-based participants and an additional 10 participants for the app in a usability study?
QE 21-3: Should I email the Templates inbox to get clarification about the number of participants required for paper-based and app-based usability studies?
QE 21-4: How does using an app for interpretation impact performance in a usability or clinical study?
QE 21-5: How does the app differ from the paper version in helping individuals perform the test?

##### Implicit Questions Extraction
QI 21-1: What is the FDA's stance on requiring separate studies for paper-based and app-based usability instructions?
QI 21-2: Is the FDA's primary focus on the usability of paper instructions due to assumed internet inaccessibility?
QI 21-3: Does the FDA recommend including both paper-based and app-based instructions in a kit to accommodate varied user access?
QI 21-4: How should developers demonstrate the performance impact of using app-based instruction within usability or clinical studies?
QI 21-5: What specific information should be included in an email to the Templates inbox to get clarification on usability study participant requirements?
QI 21-6: Under what circumstances does the FDA consider app-based interpretation to be equivalent to independently reading and interpreting a test?
QI 21-7: What performance differences between paper instructions and app-based instructions does the FDA expect developers to evaluate?
